T2 — RCT in related condition
MCAS
12 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 37024900 ↗ — The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a
- T2 12968983 ↗ — Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the ski
- T2 17324243 ↗ — Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmaco
- T6 32400125 ↗ — The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults
- T6 28289538 ↗ — Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontane
- T6INDIRECT 30944690 ↗ — Vitamin D supplements improve urticaria symptoms and quality of life in chronic spontaneous urticari
- T6INDIRECT 30402619 ↗ — Hyperresponsiveness to antihistamines in spontaneous urticaria and heat urticaria
- T6INDIRECT 25346784 ↗ — Vitamin d supplements improve urticaria symptoms and quality of life in chronic spontaneous urticari
- T4 PMC4101696 ↗ — Abstracts of the XX World Allergy CongressTM 2007 December 2–6, 2007, Bangkok, Thailand
- T6 19915710 ↗ — Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticari
- T6 32467688 ↗ — The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression o
Allogeneic Hematopoietic Stem Cell Transplantation
T2
T2 — RCT in related condition
MCAS
19 sources
- T6INDIRECT 28644114 ↗ — Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- T6INDIRECT 28694687 ↗ — Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese
- T6INDIRECT 34748627 ↗ — COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPIC
- T6INDIRECT 34608129 ↗ — Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
- T6INDIRECT 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T2 31132454 ↗ — Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
- T6INDIRECT 23935024 ↗ — Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after red
- T6INDIRECT 30922329 ↗ — Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy respons
- T6 27834397 ↗ — The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
- T6 28484466 ↗ — The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 23023713 ↗ — Pathogenesis of follicular lymphoma
- T6INDIRECT 34774343 ↗ — A review of FLT3 inhibitors in acute myeloid leukemia
- T6INDIRECT 31547472 ↗ — CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
- T6INDIRECT 31723789 ↗ — Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the Euro
- T6INDIRECT 25796139 ↗ — Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health c
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6 24136165 ↗ — The genetic basis of myelodysplasia and its clinical relevance
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
Allogeneic hematopoietic stem cell transplantation
T2
T2 — RCT in related condition
MCAS
20 sources
- T6 NCT01384513 ↗ — A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Mali
- T6INDIRECT 28644114 ↗ — Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- T6INDIRECT 28694687 ↗ — Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese
- T6INDIRECT 34748627 ↗ — COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPIC
- T6INDIRECT 34608129 ↗ — Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
- T6INDIRECT 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T2 31132454 ↗ — Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
- T6INDIRECT 23935024 ↗ — Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after red
- T6INDIRECT 30922329 ↗ — Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy respons
- T6 27834397 ↗ — The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
- T6 28484466 ↗ — The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 23023713 ↗ — Pathogenesis of follicular lymphoma
- T6INDIRECT 34774343 ↗ — A review of FLT3 inhibitors in acute myeloid leukemia
- T6INDIRECT 31547472 ↗ — CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
- T6INDIRECT 31723789 ↗ — Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the Euro
- T6INDIRECT 25796139 ↗ — Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health c
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6 24136165 ↗ — The genetic basis of myelodysplasia and its clinical relevance
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
T2 — RCT in related condition
MCAS
25 sources
- T6INDIRECT 31749986 ↗ — Efficacy and safety of topical and systemic medications: a systematic literature review informing th
- T6INDIRECT 37487610 ↗ — The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected h
- T6INDIRECT 37486733 ↗ — The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected H
- T6INDIRECT 35359659 ↗ — Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinica
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 35563242 ↗ — Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Pu
- T6INDIRECT 38139057 ↗ — The Effects of Periodontal Treatment on Rheumatoid Arthritis and of Anti-Rheumatic Drugs on Periodon
- T2 29141858 ↗ — Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recen
- T6INDIRECT 38849829 ↗ — Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart fai
- T6INDIRECT 23087179 ↗ — Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial
- T6INDIRECT 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6INDIRECT 32107531 ↗ — Pediatric hemophagocytic lymphohistiocytosis
- T6INDIRECT 32803422 ↗ — Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a com
- T6INDIRECT 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6INDIRECT 33867315 ↗ — The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives
- T6INDIRECT 35606650 ↗ — Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treat
- T6INDIRECT 29259713 ↗ — The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and prurit
- T6 26121197 ↗ — Inflammasomes: mechanism of action, role in disease, and therapeutics
- T6 31676858 ↗ — TIM3 comes of age as an inhibitory receptor
- T6 18982161 ↗ — The cytokine network in asthma and chronic obstructive pulmonary disease
- T6 25625584 ↗ — NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflamm
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 29764485 ↗ — The role of inflammation in the development of epilepsy
- T6 30774631 ↗ — The Immunology of Macrophage Activation Syndrome
- T6 22889225 ↗ — The inflammation highway: metabolism accelerates inflammatory traffic in obesity
T2 — RCT in related condition
MCAS
15 sources
- T6INDIRECT 40520797 ↗ — Clinical efficacy and safety of acupuncture in the treatment for chronic spontaneous urticaria: a sy
- T2 40415544 ↗ — Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria
- T6 39158477 ↗ — Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways
- T6 38345154 ↗ — Prurigo nodularis: new insights into pathogenesis and novel therapeutics
- T6 37717255 ↗ — Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments
- T6 37887317 ↗ — Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanism
- T6 38077377 ↗ — Molecular mechanisms of pruritus in prurigo nodularis
- T6INDIRECT 37894846 ↗ — Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases
- T6INDIRECT 38135920 ↗ — Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic
- T6INDIRECT 37386330 ↗ — Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
- T6INDIRECT 38791201 ↗ — Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
- T6INDIRECT 39028396 ↗ — New insights into chronic inducible urticaria
- T6 38630620 ↗ — Mast cells: a novel therapeutic avenue for cardiovascular diseases?
- T6 38289515 ↗ — Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabiliz
- T6 37376140 ↗ — Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy
T2 — RCT in related condition
MCAS
24 sources
- T2 NCT05449444 ↗ — Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
- T6 26462910 ↗ — Biomarkers of severe dengue disease - a review
- T6 31216696 ↗ — Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approache
- T6 32663575 ↗ — Tackling the cytokine storm in COVID-19, challenges and hopes
- T6 34382298 ↗ — Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cance
- T6 34289787 ↗ — Avapritinib for Systemic Mastocytosis
- T6INDIRECT 34660314 ↗ — Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatm
- T6INDIRECT 26179201 ↗ — Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with ad
- T6INDIRECT 38320129 ↗ — Avapritinib versus Placebo in Indolent Systemic Mastocytosis
- T6INDIRECT 28550021 ↗ — Effects of continuous positive airway pressure on neurocognitive architecture and function in patien
- T6INDIRECT 42319518 ↗ — Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nona
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 26391154 ↗ — Targeted therapy in cancer
- T6 33685604 ↗ — Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
- T6 21125679 ↗ — The GIST paradigm: lessons for other kinase-driven cancers
- T6 23829867 ↗ — Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patie
- T6INDIRECT 33672766 ↗ — Thrombocytopenia in Virus Infections
- T6INDIRECT 27843641 ↗ — ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
- T6INDIRECT 24135408 ↗ — Novel agents for multiple myeloma to overcome resistance in phase III clinical trials
- T6INDIRECT 32462367 ↗ — Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates
- T6INDIRECT 34178645 ↗ — Perspectives on Immunotherapy of Metastatic Colorectal Cancer
- T6INDIRECT 34295668 ↗ — International consensus on severe lung cancer-the first edition
- T6INDIRECT 30327374 ↗ — The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patien
- T6 24605265 ↗ — Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
T2 — RCT in related condition
MCAS
5 sources
- T2 39351222 ↗ — Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chro
- T6 33785991 ↗ — Expertenkonsensus zu praxisrelevanten Aspekten bei der Behandlung der chronischen Urtikaria
- T6 28035215 ↗ — The role and choice criteria of antihistamines in allergy management - expert opinion
- T6 37626727 ↗ — Chronic Urticaria Biomarkers IL-6, ESR and CRP in Correlation with Disease Severity and Patient Qual
- T6 40745660 ↗ — 2024 CSACI Annual Scientific Meeting Book of Abstracts
T2 — RCT in related condition
MCAS
20 sources
- T6 NCT01807598 ↗ — Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
- T2 28010897 ↗ — Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review
- T6INDIRECT 40422524 ↗ — Patient-Reported Outcome Measures (PROMS) in Lymphoma
- T6INDIRECT 42068413 ↗ — Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer
- T6INDIRECT 34904799 ↗ — Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
- T6INDIRECT 26109102 ↗ — Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
- T6INDIRECT 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T6 33657296 ↗ — Diffuse Large B-Cell Lymphoma
- T6 26679767 ↗ — Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive
- T6 28885612 ↗ — Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight int
- T6 28254862 ↗ — Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the
- T6INDIRECT 35790816 ↗ — Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocyt
- T5 26994848 ↗ — Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 29052609 ↗ — Neuro-ophthalmic side effects of molecularly targeted cancer drugs
- T6 26654227 ↗ — Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell l
- T6 35217782 ↗ — New treatment strategies for advanced-stage gastrointestinal stromal tumours
- T6 30677473 ↗ — Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposit
- T6 33291602 ↗ — Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
T2 — RCT in related condition
MCAS
17 sources
- T2 39785096 ↗ — CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Bl
- T6 40074986 ↗ — Update on the Treatment of Chronic Spontaneous Urticaria
- T6 33289684 ↗ — Immune Response to <i>Borrelia</i>: Lessons from Lyme Disease Spirochetes
- T6 23790098 ↗ — Bell's palsy and sudden deafness associated with Rickettsia spp. infection in Sweden. A retrospectiv
- T6 36434739 ↗ — Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised,
- T6INDIRECT 42128382 ↗ — Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines
- T6INDIRECT 41809769 ↗ — Treatments and Targets to Achieve Disease Control in Chronic Spontaneous Urticaria: Current and Emer
- T4 PMC5103240 ↗ — 6th International Symposium on Molecular Allergology (ISMA)
- T4 PMC7159569 ↗ — Abstracts: Poster session
- T4 PMC11627186 ↗ — ACNP 63rd Annual Meeting: Poster Abstracts P1-P304
- T4 PMC11535630 ↗ — OA20 Differentiating Lupus Nephritis from Pre-eclampsia-A Diagnostic Dilemma
- T4 PMC7917173 ↗ — Abstracts of the 87th Annual Meeting of the German Society for Experimental and Clinical Pharmacolog
- T6 36839989 ↗ — Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
- T6 41654334 ↗ — Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
- T6 41270830 ↗ — Emerging IgE and non-IgE targeted therapies for chronic urticaria
- T6 1633419 ↗ — Oncogenes and cell proliferation
- T6 40747638 ↗ — Biologic and small molecule therapies in chronic spontaneous urticaria: an update
T2 — RCT in related condition
MCAS
21 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 33206207 ↗ — Histamine receptors and COVID-19
- T6INDIRECT 17253584 ↗ — H1-antihistamines for the treatment of anaphylaxis with and without shock
- T6INDIRECT 23450580 ↗ — Oral H1 antihistamines as monotherapy for eczema
- T6INDIRECT 28342911 ↗ — Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis
- T2 2874958 ↗ — Terfenadine in chronic urticaria: a comparison with clemastine and placebo
- T6INDIRECT 1715267 ↗ — Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhiniti
- T2 2650586 ↗ — Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study w
- T6 29949830 ↗ — Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
- T6 33204386 ↗ — World allergy organization anaphylaxis guidance 2020
- T6INDIRECT 28965641 ↗ — Severe Delayed Drug Reactions: Role of Genetics and Viral Infections
- T6INDIRECT 36983108 ↗ — Bone Cement and Its Anesthetic Complications: A Narrative Review
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6INDIRECT 23282578 ↗ — H1 antihistamines: current status and future directions
- T6INDIRECT 26120521 ↗ — Guideline for acute therapy and management of anaphylaxis: S2 Guideline of the German Society for Al
- T6 30007465 ↗ — Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features
- T6 35744757 ↗ — Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Patho
- T6 30965592 ↗ — The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines i
- T6 33657648 ↗ — Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene gl
T2 — RCT in related condition
RegisteredME/CFSMCASPOTS
70 sources
- T2 NCT02444091 ↗ — Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)
- T6 NCT01384513 ↗ — A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Mali
- T6REGISTERED-ONLY NCT03779854 ↗ — Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults
- T6INDIRECT 21491378 ↗ — Interventions for preventing oral mucositis for patients with cancer receiving treatment
- T6INDIRECT 20687070 ↗ — Interventions for treating oral mucositis for patients with cancer receiving treatment
- T6INDIRECT 36103991 ↗ — Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 d
- T6INDIRECT 36228963 ↗ — Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline patho
- T6INDIRECT 23599118 ↗ — Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical tr
- T6INDIRECT 15471655 ↗ — Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer
- T6INDIRECT 26844275 ↗ — Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: R
- T6 2683611 ↗ — Biology of natural killer cells
- T6 10515901 ↗ — Q fever
- T6 32762681 ↗ — Natural killer cells in cancer biology and therapy
- T6 19375665 ↗ — Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
- T6 9560217 ↗ — Bax directly induces release of cytochrome c from isolated mitochondria
- T6INDIRECT 20548096 ↗ — Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-
- T6INDIRECT 34904799 ↗ — Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
- T2 30901302 ↗ — Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristin
- T6INDIRECT 36542826 ↗ — Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the p
- T6INDIRECT 30184451 ↗ — Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- T6INDIRECT 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T6INDIRECT 30811293 ↗ — First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Ben
- T6INDIRECT 20431041 ↗ — Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and l
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T6INDIRECT 25842160 ↗ — Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a
- T6INDIRECT 34542573 ↗ — Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephaliti
- T6INDIRECT 26561338 ↗ — Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
- T6INDIRECT 29217664 ↗ — Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Re
- T6INDIRECT 29271481 ↗ — Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
- T6INDIRECT 30361325 ↗ — DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
- T6INDIRECT 32244252 ↗ — Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of A
- T6INDIRECT 1739631 ↗ — Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
- T6INDIRECT 8774401 ↗ — Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal auto
- T6 36695182 ↗ — Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association
- T6 38264914 ↗ — 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Ass
- T6INDIRECT 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 24247168 ↗ — Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- T6INDIRECT 29523094 ↗ — Pediatric multiple sclerosis: a review
- T6INDIRECT 29186062 ↗ — Viral Oncology: Molecular Biology and Pathogenesis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6 34630027 ↗ — Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
- T6 22544865 ↗ — Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action,
- T6 25315420 ↗ — Autoimmune encephalopathies
- T6 29344421 ↗ — Anti-Aging Implications of <i>Astragalus Membranaceus</i> (Huangqi): A Well-Known Chinese Tonic
- T6INDIRECT 28242845 ↗ — Focal Segmental Glomerulosclerosis
- T6INDIRECT 33649022 ↗ — Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management
- T6INDIRECT 32106302 ↗ — Overview of Castleman disease
- T6INDIRECT 28213891 ↗ — Opioids and the immune system - friend or foe
- T6INDIRECT 35215786 ↗ — <i>Herpes zoster</i>: A Review of Clinical Manifestations and Management
- T6INDIRECT 29915719 ↗ — Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy
- T6INDIRECT 27777266 ↗ — A Proposal for a Serology-Based Approach to Membranous Nephropathy
- T6 32433595 ↗ — Interaction between microbiota and immunity in health and disease
- T6 32934330 ↗ — Exploring the NK cell platform for cancer immunotherapy
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6 19597008 ↗ — Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis
- T6 26228647 ↗ — Colchicine--Update on mechanisms of action and therapeutic uses
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 28550082 ↗ — Primary Membranous Nephropathy
- T6 33657296 ↗ — Diffuse Large B-Cell Lymphoma
- T6INDIRECT 30049614 ↗ — Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex ence
- T6INDIRECT 24462240 ↗ — Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a c
- T6INDIRECT 24703753 ↗ — A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder assoc
- T6INDIRECT 39866113 ↗ — 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Ass
- T6INDIRECT 24423978 ↗ — Adrenocortical carcinoma
- T6INDIRECT 29442540 ↗ — Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor The
- T6 31871779 ↗ — Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
- T6 32231332 ↗ — Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- T6 32792490 ↗ — Podocytopathies
- T6 34988090 ↗ — Treatment of Inflammatory Bowel Disease: A Comprehensive Review
- T6 24323045 ↗ — Autophagy and human diseases
T2 — RCT in related condition
MCAS
22 sources
- T6INDIRECT 25919144 ↗ — Interventions for rosacea
- T6INDIRECT 22972085 ↗ — Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)
- T6INDIRECT 32176310 ↗ — A Systematic Review of Drug-Induced Pemphigoid
- T6INDIRECT 21812866 ↗ — Urban legends: recurrent aphthous stomatitis
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 34431983 ↗ — Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
- T6INDIRECT 30879003 ↗ — Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontan
- T2 25213055 ↗ — Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urti
- T6INDIRECT 19330244 ↗ — Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial
- T6INDIRECT 18484427 ↗ — Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on hi
- T6INDIRECT 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 30558872 ↗ — Antibiotic allergy
- T6INDIRECT 11788573 ↗ — The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases
- T6INDIRECT 26254049 ↗ — Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathoge
- T6INDIRECT 28832953 ↗ — Colchicine: an ancient drug with novel applications
- T6INDIRECT 35606650 ↗ — Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treat
- T6INDIRECT 31513026 ↗ — Celiac Disease: Extraintestinal Manifestations and Associated Conditions
- T6INDIRECT 27866580 ↗ — Eosinophilia
- T6 24310318 ↗ — Dapsone in dermatology and beyond
- T6 30573342 ↗ — Controversies in drug allergy: Testing for delayed reactions
- T6 10987697 ↗ — Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease
- T6 16437620 ↗ — Extraintestinal manifestations in inflammatory bowel disease
T2 — RCT in related condition
MCAS
20 sources
- T2 19187278 ↗ — Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with
- T6 30347635 ↗ — New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases
- T6 25079860 ↗ — Acute interstitial nephritis - a reappraisal and update
- T6 19951979 ↗ — Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasiro
- T6 28121072 ↗ — Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development
- T6INDIRECT 30805232 ↗ — Mucormycotic Osteomyelitis Involving the Maxilla: A Rare Case Report and Review of the Literature
- T6INDIRECT 36046774 ↗ — Efficacy of CRISPR-Based Gene Editing in a Sickle Cell Disease Patient as Measured through the Eye
- T6INDIRECT 36278522 ↗ — Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Liter
- T6INDIRECT 38928368 ↗ — Copper, Iron, Cadmium, and Arsenic, All Generated in the Universe: Elucidating Their Environmental I
- T6INDIRECT 28919773 ↗ — Sickle cell retinopathy: improving care with a multidisciplinary approach
- T6INDIRECT 35079682 ↗ — Dilemmas in the Management of Osteoporosis in Younger Adults
- T6INDIRECT 36588206 ↗ — Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review
- T6INDIRECT 19898904 ↗ — High-affinity alphavbeta3 integrin targeted optical probe as a new imaging biomarker for early ather
- T6 22300258 ↗ — Non-systemic drugs: a critical review
- T6 31474092 ↗ — Proximal renal tubular acidosis with and without Fanconi syndrome
- T6 28149844 ↗ — Companion diagnostics-a tool to improve pharmacotherapy
- T6 33143139 ↗ — Iron Assimilation during Emerging Infections Caused by Opportunistic Fungi with emphasis on Mucorale
- T6 39596504 ↗ — Drug Repurposing for Cancer Treatment: A Comprehensive Review
- T6 33919446 ↗ — Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque
- T6 22924125 ↗ — Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia a
T2 — RCT in related condition
MCAS
28 sources
- T6 NCT03401060 ↗ — Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
- T6INDIRECT 35628390 ↗ — Meta-Analysis of Two Human RNA-seq Datasets to Determine Periodontitis Diagnostic Biomarkers and Dru
- T6INDIRECT 40965250 ↗ — Association of body mass index and bone mineral density in postmenopausal women: a systematic review
- T6INDIRECT 40485004 ↗ — Implant Survival in Patient Populations With a Mean Age of 65-75 Years Compared to Older Cohorts: A
- T6INDIRECT 27706804 ↗ — Bisphosphonates for steroid-induced osteoporosis
- T6INDIRECT 38820458 ↗ — Increased Prevalence of Periapical Lesions in Osteoporosis Patients: A Systematic Review
- T2 40309441 ↗ — Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous
- T6INDIRECT 31482156 ↗ — Are drug-related dental management cautions in Lexicomp Online for Dentistry evidence-based? A syste
- T2 40612431 ↗ — The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteop
- T2 42181204 ↗ — Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosph
- T6INDIRECT 33123580 ↗ — Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases
- T5 32373677 ↗ — Rebound-associated vertebral fractures may occur in sequential time points following denosumab disco
- T6INDIRECT 24766381 ↗ — Osteoporosis prevention, screening, and treatment: a review
- T6INDIRECT 27132234 ↗ — Pharmacological treatment options for mast cell activation disease
- T6INDIRECT 24044484 ↗ — Mastocytosis: update on pharmacotherapy and future directions
- T6INDIRECT 39596206 ↗ — Primary Osteoporosis Induced by Androgen and Estrogen Deficiency: The Molecular and Cellular Perspec
- T6INDIRECT 28131128 ↗ — Premenopausal Osteoporosis
- T6INDIRECT 36292765 ↗ — Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management
- T6INDIRECT 21224201 ↗ — American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the d
- T6 25810047 ↗ — Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma
- T6 32844416 ↗ — Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy
- T6 21753790 ↗ — Advances in sarcoma genomics and new therapeutic targets
- T6 36012730 ↗ — Current Status of the Diagnosis and Management of Osteoporosis
- T6 25971649 ↗ — Management of endocrine disease: Secondary osteoporosis: pathophysiology and management
- T6 26150706 ↗ — Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives
- T6 30324412 ↗ — European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- T6 23079689 ↗ — European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- T6 25182228 ↗ — Clinician's Guide to Prevention and Treatment of Osteoporosis
T2 — RCT in related condition
WithdrawnMCAS
1 source
- T2WITHDRAWN NCT05652907 ↗ — Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCA
T2 — RCT in related condition
MCAS
18 sources
- T6INDIRECT 40611956 ↗ — Impact of <i>Helicobacter pylori</i> infection on iron deficiency anemia in children: a
- T6INDIRECT 22870245 ↗ — Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse
- T2 34782532 ↗ — Comparison of efficacy & safety of iron polymaltose complex & ferrous ascorbate with ferrous sulphat
- T6INDIRECT 22858697 ↗ — Iron supplementation reduces the erosive potential of a cola drink on enamel and dentin in situ
- T6 32655238 ↗ — Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (P
- T6 38928368 ↗ — Copper, Iron, Cadmium, and Arsenic, All Generated in the Universe: Elucidating Their Environmental I
- T6 25266247 ↗ — Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task fo
- T6 32614911 ↗ — Detecting rare diseases in electronic health records using machine learning and knowledge engineerin
- T6 38290531 ↗ — Investigating intestinal mast cell dynamics during acute heat stress in growing pigs
- T6INDIRECT 26134967 ↗ — Pseudomelanosis of the stomach and duodenum: an uncommon endoscopic finding
- T6INDIRECT 28480101 ↗ — Cervical Necrotizing Fasciitis: A Potentially Fatal Disease with Varied Etiology
- T6INDIRECT 25889707 ↗ — Valsalva retinopathy in pregnancy: a case report
- T6INDIRECT 22593635 ↗ — Pruritus in the elderly: clinical approaches to the improvement of quality of life
- T6INDIRECT 28397154 ↗ — Abstracts from the 2017 Society of General Internal Medicine Annual Meeting
- T6 39596504 ↗ — Drug Repurposing for Cancer Treatment: A Comprehensive Review
- T6 36978841 ↗ — Antioxidant Materials in Oral and Maxillofacial Tissue Regeneration: A Narrative Review of the Liter
- T6 40137174 ↗ — Diverse Physiological Roles of Kynurenine Pathway Metabolites: Updated Implications for Health and D
- T6 22184416 ↗ — Alkyl hydroperoxide reductase is required for Helicobacter cinaedi intestinal colonization and survi
T2 — RCT in related condition
RegisteredWithdrawnMCASPOTS
42 sources
- T6WITHDRAWN NCT01773395 ↗ — GVAX vs. Placebo for MDS/AML After Allo HSCT
- T6 NCT01384513 ↗ — A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Mali
- T6REGISTERED-ONLY NCT03779854 ↗ — Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults
- T6INDIRECT 36542826 ↗ — Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the p
- T2 12393618 ↗ — Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) reg
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T2 8648382 ↗ — Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma
- T6INDIRECT 38659046 ↗ — Long-term remission and survival in patients with relapsed or refractory multiple myeloma after trea
- T2 15741224 ↗ — Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine,
- T6 32934330 ↗ — Exploring the NK cell platform for cancer immunotherapy
- T6 11229815 ↗ — The CD40/CD154 receptor/ligand dyad
- T6 29915719 ↗ — Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy
- T6 24859366 ↗ — Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid d
- T6INDIRECT 37756687 ↗ — Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta
- T6INDIRECT 28971751 ↗ — Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta
- T6INDIRECT 29217664 ↗ — Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Re
- T6INDIRECT 19263294 ↗ — Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory
- T6 31871779 ↗ — Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
- T6 29442540 ↗ — Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor The
- T6 33895845 ↗ — 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral A
- T6 31210940 ↗ — European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gl
- T6 22308288 ↗ — CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 a
- T6 22762314 ↗ — Eltrombopag and improved hematopoiesis in refractory aplastic anemia
- T6INDIRECT 30705099 ↗ — IgG4-related disease: what a hematologist needs to know
- T6INDIRECT 34774343 ↗ — A review of FLT3 inhibitors in acute myeloid leukemia
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 33875812 ↗ — Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approac
- T6INDIRECT 29475724 ↗ — A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a
- T6 19099185 ↗ — Mcl-1 is a potential therapeutic target in multiple types of cancer
- T6 22075983 ↗ — BCL2A1: the underdog in the BCL2 family
- T6 24975478 ↗ — Getting Syk: spleen tyrosine kinase as a therapeutic target
- T6 23060872 ↗ — Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodefici
- T6INDIRECT 30348186 ↗ — Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and mult
- T6INDIRECT 34134525 ↗ — Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A
- T6INDIRECT 37345050 ↗ — The Black Hole: CAR T Cell Therapy in AML
- T6INDIRECT 25124015 ↗ — Noninvasive imaging of cardiovascular injury related to the treatment of cancer
- T6 30130469 ↗ — Iron and Cancer
- T6 28174091 ↗ — Inhibitors of cyclin-dependent kinases as cancer therapeutics
- T6 25561510 ↗ — Advances in anticancer immunotoxin therapy
- T6 26566663 ↗ — The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel th
- T6 26391778 ↗ — Cancer-treatment-induced neurotoxicity--focus on newer treatments
T2 — RCT in related condition
MCAS
21 sources
- T6INDIRECT 35563242 ↗ — Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Pu
- T6INDIRECT 22895957 ↗ — Antivirals for idiopathic sudden sensorineural hearing loss
- T6INDIRECT 16236177 ↗ — A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients
- T6INDIRECT 26037730 ↗ — Acupuncture for the sequelae of Bell's palsy: a randomized controlled trial
- T6INDIRECT 38587846 ↗ — Intravesical Interferon Therapy vs Hyaluronic Acid for Pain Among Female Individuals With Interstiti
- T6INDIRECT 21388554 ↗ — Acupuncture for sequelae of Bell's palsy: a randomized controlled trial protocol
- T2 25563312 ↗ — Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex kera
- T6INDIRECT 39506756 ↗ — Therapeutic effects of acyclovir and acyclovir-clobetasol nanofibers vs. cream formulation for recur
- T6 35215786 ↗ — <i>Herpes zoster</i>: A Review of Clinical Manifestations and Management
- T6 33219338 ↗ — Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease
- T6INDIRECT 35343828 ↗ — Salivary gland function, development, and regeneration
- T6INDIRECT 21277939 ↗ — Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 32963819 ↗ — Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the
- T6INDIRECT 33485845 ↗ — Systemic diseases and the cornea
- T6 11842096 ↗ — Natural and pharmacological regulation of telomerase
- T6 39326415 ↗ — Mechanisms of long COVID and the path toward therapeutics
- T6 36899952 ↗ — Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutic
- T6 15085193 ↗ — Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial fa
- T6 24138883 ↗ — Th9 Cells Drive Host Immunity against Gastrointestinal Worm Infection
T2 — RCT in related condition
MCAS
20 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6INDIRECT 38103150 ↗ — Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network M
- T6INDIRECT 37455197 ↗ — Pharmacological agents for prevention of pruritus in women undergoing Caesarean delivery with neurax
- T6INDIRECT 32546683 ↗ — A comprehensive map of disease networks and molecular drug discoveries for glaucoma
- T2 11197756 ↗ — Immediate effects of the serotonin antagonist granisetron on temporomandibular joint pain in patient
- T6INDIRECT 37288512 ↗ — The effect of pharyngeal packing on gastric volume in patients undergoing nasal surgery: a randomise
- T6INDIRECT 22733017 ↗ — Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
- T6 33370241 ↗ — International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydrox
- T6 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6 35964548 ↗ — Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- T6 28240194 ↗ — Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract
- T6INDIRECT 21767775 ↗ — Pruritus: management algorithms and experimental therapies
- T6INDIRECT 20137004 ↗ — Emesis in dogs: a review
- T6INDIRECT 24251966 ↗ — Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis
- T6INDIRECT 23403690 ↗ — Mechanisms, causes, investigation and management of vomiting disorders in cats: a literature review
- T6 35145413 ↗ — Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional G
- T6 38516587 ↗ — Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies
- T6 32696221 ↗ — Enhancement of skin permeability with thermal ablation techniques: concept to commercial products
- T6 37933613 ↗ — Pyrazole: an emerging privileged scaffold in drug discovery
- T6 26635531 ↗ — Gastrointestinal Parasites and the Neural Control of Gut Functions
T2 — RCT in related condition
MCAS
26 sources
- T6INDIRECT 30427977 ↗ — Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic
- T6INDIRECT 29392757 ↗ — Chronic spontaneous urticaria in children - a systematic review on interventions and comorbidities
- T2 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T6INDIRECT 28435464 ↗ — Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of F
- T6INDIRECT 28069279 ↗ — Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placeb
- T6INDIRECT 34750553 ↗ — Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized p
- T6INDIRECT 15086698 ↗ — Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and ev
- T6INDIRECT 19453774 ↗ — The use of a responder analysis to identify clinically meaningful differences in chronic urticaria p
- T6INDIRECT 28160338 ↗ — H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first result
- T6INDIRECT 6114712 ↗ — Combined H1 and H2 antihistamine therapy in chronic urticaria
- T6INDIRECT 32196678 ↗ — Eleven faces of coronavirus disease 2019
- T6INDIRECT 32436290 ↗ — EAACI Allergen Immunotherapy User's Guide
- T6INDIRECT 21668033 ↗ — Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations
- T6INDIRECT 31256161 ↗ — Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activat
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6 26779180 ↗ — Mast Cell: A Multi-Functional Master Cell
- T6 30150993 ↗ — The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hu
- T6 28780941 ↗ — The pathophysiology of anaphylaxis
- T6 29949830 ↗ — Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
- T6 33204386 ↗ — World allergy organization anaphylaxis guidance 2020
- T6 24679069 ↗ — Sublingual immunotherapy: World Allergy Organization position paper 2013 update
- T6 21134576 ↗ — Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAI
- T6 23268454 ↗ — World allergy organization guidelines for the assessment and management of anaphylaxis
T2 — RCT in related condition
MCAS
18 sources
- T2 32895648 ↗ — Prenatal or Childhood Serum Levels of Vitamin D and Dental Caries in Paediatric Patients: A Systemat
- T2 40745339 ↗ — Chronic urticaria and vitamin D supplementations: a systematic review
- T6INDIRECT 40205160 ↗ — Do clinical caries-preventive interventions applied to expectant mothers affect caries-related param
- T2 24507460 ↗ — Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study
- T2 35774395 ↗ — High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With <i>Cl
- T6 34445803 ↗ — The Impact of Vitamin D on Skin Aging
- T6 31632510 ↗ — Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy
- T6 27014952 ↗ — Vitamin D in atopic dermatitis, chronic urticaria and allergic contact dermatitis
- T6 37560437 ↗ — Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a
- T6 32503654 ↗ — Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and
- T5 30944690 ↗ — Vitamin D supplements improve urticaria symptoms and quality of life in chronic spontaneous urticari
- T4 40681996 ↗ — Vitamin D and skin disorders: bridging molecular insights to clinical innovations
- T4 30534360 ↗ — Relationship between vitamin D and chronic spontaneous urticaria: a systematic review
- T4 25346784 ↗ — Vitamin d supplements improve urticaria symptoms and quality of life in chronic spontaneous urticari
- T6 25976440 ↗ — A 60-year-old woman with recurrent episodes of flushing, urticaria, and angioedema
- T6 40551736 ↗ — Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health
- T6 39796035 ↗ — Skin Disorders and Osteoporosis: Unraveling the Interplay Between Vitamin D, Microbiota, and Epigene
- T6 41846928 ↗ — Vitamin D<sub>3</sub> as an immunomodulatory agent: molecular mechanisms, clinical trans
T2 — RCT in related condition
MCAS
26 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6INDIRECT 25420283 ↗ — Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
- T6INDIRECT 25900167 ↗ — High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature
- T6INDIRECT 12804509 ↗ — Physiotherapy interventions for shoulder pain
- T6INDIRECT 21812866 ↗ — Urban legends: recurrent aphthous stomatitis
- T6INDIRECT 28192644 ↗ — Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery
- T6INDIRECT 26132597 ↗ — Topical tacrolimus for atopic dermatitis
- T6INDIRECT 23936562 ↗ — Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine pr
- T6INDIRECT 23041624 ↗ — T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection
- T2 7865982 ↗ — Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospho
- T6 19560575 ↗ — Intestinal barrier function: molecular regulation and disease pathogenesis
- T6INDIRECT 23939821 ↗ — Key role of CRF in the skin stress response system
- T6INDIRECT 32803422 ↗ — Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a com
- T6INDIRECT 21277939 ↗ — Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy
- T6INDIRECT 24813302 ↗ — Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of a
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6INDIRECT 19143700 ↗ — Suspected anaphylactic reactions associated with anaesthesia
- T6 11229815 ↗ — The CD40/CD154 receptor/ligand dyad
- T6 33961029 ↗ — Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management
- T6 33204386 ↗ — World allergy organization anaphylaxis guidance 2020
- T6 30449684 ↗ — Quantitative Analysis of the Whole-Body Metabolic Fate of Branched-Chain Amino Acids
- T6 19926814 ↗ — Early weaning stress impairs development of mucosal barrier function in the porcine intestine
- T6 24531552 ↗ — Bitter and sweet taste receptors regulate human upper respiratory innate immunity
- T6 24153250 ↗ — Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans
- T6 28346442 ↗ — Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
T2 — RCT in related condition
MCAS
17 sources
- T2 25793707 ↗ — Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind r
- T6INDIRECT 41223203 ↗ — Analgesic effectiveness of wound infiltration with bupivacaine versus a mixture of bupivacaine and t
- T6INDIRECT 21119866 ↗ — Suspected systemic calcinosis and calciphylaxis in 5 horses
- T6 20886011 ↗ — Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review
- T6 34096653 ↗ — Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran
- T6 22927730 ↗ — Current options for the treatment of optic neuritis
- T6INDIRECT 33834172 ↗ — Prolonged Anaphylaxis to Pfizer Coronavirus Disease 2019 Vaccine: A Case Report and Mechanism of Act
- T6INDIRECT 36817292 ↗ — Hypocomplementemic Urticarial Vasculitis Syndrome Masquerading as Systemic Lupus Erythematosus: A Ca
- T6INDIRECT 30899622 ↗ — Anaphylaxis Induced by Sugammadex in a Patient with Papillary Serous Carcinoma of the Uterine Adnexa
- T6INDIRECT 32725471 ↗ — Abstracts from the 2020 Annual Meeting of the Society of General Internal Medicine
- T6INDIRECT 28397154 ↗ — Abstracts from the 2017 Society of General Internal Medicine Annual Meeting
- T6 38690390 ↗ — Ocular involvement in oral vesiculobullous diseases: A review on reported cases in the literature
- T6 32745248 ↗ — Abstracts from the European Academy of Allergy and Clinical Immunology Congress, 26-30 May 2018, Mun
- T6 27114361 ↗ — Abstracts from the 2016 Society of General Internal Medicine Annual Meeting
- T6 35252582 ↗ — Main Abstracts
- T6 35295545 ↗ — Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
- T6 34828527 ↗ — State of the Art in Hepatic Dysfunction in Pregnancy
T2 — RCT in related condition
MCAS
24 sources
- T6INDIRECT 34431983 ↗ — Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
- T6INDIRECT 34695599 ↗ — Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response t
- T6INDIRECT 37572360 ↗ — Interventions for bullous pemphigoid
- T2 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6INDIRECT 34750553 ↗ — Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized p
- T2 38008109 ↗ — Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: res
- T2 37492920 ↗ — Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b rando
- T6INDIRECT 40415544 ↗ — Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria
- T6INDIRECT 37545503 ↗ — Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with
- T6 35667749 ↗ — Autoimmune chronic spontaneous urticaria
- T6INDIRECT 29259713 ↗ — The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and prurit
- T6INDIRECT 28097159 ↗ — IgE-Related Chronic Diseases and Anti-IgE-Based Treatments
- T6INDIRECT 31636640 ↗ — The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid
- T6INDIRECT 30882368 ↗ — The use of biologics for immune modulation in allergic disease
- T6INDIRECT 32421085 ↗ — Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in
- T6INDIRECT 30021447 ↗ — Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
- T6INDIRECT 37190096 ↗ — Mast Cells as a Target-A Comprehensive Review of Recent Therapeutic Approaches
- T6INDIRECT 27826958 ↗ — Personalized Medicine in Allergy
- T6 36928371 ↗ — The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
- T6 32929378 ↗ — Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precisi
- T6 39962262 ↗ — Type 2 immunity in allergic diseases
- T6 33807098 ↗ — Pruritus as a Distinctive Feature of Type 2 Inflammation
- T6 32224621 ↗ — Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020
- T6 35469840 ↗ — KIT as a master regulator of the mast cell lineage
T2 — RCT in related condition
MCAS
2 sources
- T2 35268051 ↗ — Vitamin D Supplementation and Sleep: A Systematic Review and Meta-Analysis of Intervention Studies
- T6 30534360 ↗ — Relationship between vitamin D and chronic spontaneous urticaria: a systematic review
T2 — RCT in related condition
MCAS
1 source
- T2 NCT05449444 ↗ — Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
T2 — RCT in related condition
RegisteredWithdrawnMCASPOTS
51 sources
- T6WITHDRAWN NCT01773395 ↗ — GVAX vs. Placebo for MDS/AML After Allo HSCT
- T6REGISTERED-ONLY NCT03779854 ↗ — Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults
- T2 21855836 ↗ — Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease
- T6INDIRECT 31046809 ↗ — Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arth
- T6INDIRECT 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T6INDIRECT 30943337 ↗ — Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome
- T6INDIRECT 30343531 ↗ — Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-
- T6INDIRECT 35671774 ↗ — Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
- T6INDIRECT 28435464 ↗ — Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of F
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T6INDIRECT 25789989 ↗ — A pilot study of omalizumab in eosinophilic esophagitis
- T6 35732831 ↗ — The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid
- T6INDIRECT 32114706 ↗ — Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- T6INDIRECT 29744873 ↗ — Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - as
- T6INDIRECT 34542573 ↗ — Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephaliti
- T6INDIRECT 28816346 ↗ — Homocysteine-lowering interventions for preventing cardiovascular events
- T6INDIRECT 30019766 ↗ — Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- T6INDIRECT 30521670 ↗ — Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- T6INDIRECT 26561338 ↗ — Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
- T6INDIRECT 27382171 ↗ — Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid a
- T6INDIRECT 1739631 ↗ — Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
- T6INDIRECT 17965121 ↗ — Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of respo
- T6INDIRECT 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6INDIRECT 32107531 ↗ — Pediatric hemophagocytic lymphohistiocytosis
- T6INDIRECT 33077936 ↗ — Kinase inhibition in autoimmunity and inflammation
- T6INDIRECT 35215786 ↗ — <i>Herpes zoster</i>: A Review of Clinical Manifestations and Management
- T6INDIRECT 29915719 ↗ — Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy
- T6INDIRECT 24366648 ↗ — Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations
- T6INDIRECT 23109216 ↗ — Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for p
- T6 34824210 ↗ — The JAK/STAT signaling pathway: from bench to clinic
- T6 21303899 ↗ — International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of ad
- T6 18758473 ↗ — Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
- T6 25287861 ↗ — Calcitonin gene-related peptide: physiology and pathophysiology
- T6 24587990 ↗ — Oxidative stress, prooxidants, and antioxidants: the interplay
- T6 38311623 ↗ — Extracellular vesicles as tools and targets in therapy for diseases
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6INDIRECT 30218025 ↗ — Mechanisms, biomarkers and targets for adult-onset Still's disease
- T6INDIRECT 35655306 ↗ — Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine
- T6INDIRECT 31954495 ↗ — Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- T6INDIRECT 34655433 ↗ — Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
- T6INDIRECT 24672257 ↗ — Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
- T6INDIRECT 31485575 ↗ — Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
- T6INDIRECT 29442540 ↗ — Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor The
- T6 37919282 ↗ — Smart nanoparticles for cancer therapy
- T6 34988090 ↗ — Treatment of Inflammatory Bowel Disease: A Comprehensive Review
- T6 32213941 ↗ — Chemical Constituents and Pharmacological Activities of Garlic (<i>Allium sativum</i> L.): A Review
- T6 29163522 ↗ — The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Trac
- T6 31633216 ↗ — Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
- T6 25182228 ↗ — Clinician's Guide to Prevention and Treatment of Osteoporosis
- T6 35478046 ↗ — The clinician's guide to prevention and treatment of osteoporosis
T2 — RCT in related condition
MCAS
22 sources
- T6INDIRECT 35968291 ↗ — Rhythmic auditory stimulation promotes gait recovery in Parkinson's patients: A systematic review an
- T2 37735362 ↗ — A systematic review and network meta-analysis of virtual reality, audiovisuals and music interventio
- T6INDIRECT 22978561 ↗ — Ending homelessness among people with mental illness: the At Home/Chez Soi randomized trial of a Hou
- T2 30545420 ↗ — Music therapy intervention in cardiac autonomic modulation, anxiety, and depression in mothers of pr
- T6INDIRECT 27769226 ↗ — The effectiveness of a Housing First adaptation for ethnic minority groups: findings of a pragmatic
- T6INDIRECT 23031406 ↗ — Moving from rhetoric to reality: adapting Housing First for homeless individuals with mental illness
- T2 32401941 ↗ — Effect of music at 432 Hz and 440 Hz on dental anxiety and salivary cortisol levels in patients unde
- T6INDIRECT 25887511 ↗ — Effectiveness and cost-effectiveness of cognitive adaptation training as a nursing intervention in l
- T6INDIRECT 32399126 ↗ — Effects of Rhythmic Sensory Stimulation on Ehlers-Danlos Syndrome: A Pilot Study
- T6 27843641 ↗ — ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
- T6INDIRECT 35401253 ↗ — Psychological Interventions for Young People With Psychotic Disorders: A Systematic Review
- T6INDIRECT 39428602 ↗ — Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With
- T6INDIRECT 34444622 ↗ — An Integrative Review of Recovery Services to Improve the Lives of Adults Living with Severe Mental
- T6INDIRECT 41009795 ↗ — Advances in Psoriasis Research: Decoding Immune Circuits and Developing Novel Therapies
- T6INDIRECT 30240102 ↗ — Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP) Kyoto, J
- T6INDIRECT 40726475 ↗ — 11th European Stroke Organisation Conference Abstracts - 21-23 May 2025, Helsinki, Finland
- T6 39273008 ↗ — Gut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders
- T6 36674580 ↗ — Alzheimer's Disease-Biochemical and Psychological Background for Diagnosis and Treatment
- T6 40792123 ↗ — The China Alzheimer Report 2025
- T6 30993550 ↗ — Update in Neurocritical Care: a summary of the 2018 Paris international conference of the French Soc
- T6 30588066 ↗ — Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management
- T6 26541397 ↗ — Methods of reducing pain during bone marrow biopsy: a narrative review
Ophthalmological examination
T2
T2 — RCT in related condition
MCAS
28 sources
- T2 NCT04978740 ↗ — Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
- T6 30242621 ↗ — Latest Clinical Approaches in the Ocular Management of Cystinosis: A Review of Current Practice and
- T6 30965123 ↗ — Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host di
- T6 33928457 ↗ — Effects of acute alcohol consumption on neuronal activity and cerebral vasomotor response
- T6 29977446 ↗ — Neurologic Complications of Acute Posterior Multifocal Placoid Pigment Epitheliopathy: A Case Series
- T6 32722267 ↗ — Evaluation of Subchronic Oral Dose Toxicity of Freeze-Dried Skimmed Powder of <i>Zophobas atratus</i
- T6INDIRECT 25919144 ↗ — Interventions for rosacea
- T6INDIRECT 27373108 ↗ — COGAN'S SYNDROME
- T6INDIRECT 38407686 ↗ — Visual outcomes and patient satisfaction after bilateral implantation of an enhanced monofocal intra
- T6INDIRECT 24429379 ↗ — Impact of patient access to Internet health records on glaucoma medication: randomized controlled tr
- T6INDIRECT 32059021 ↗ — Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis
- T6INDIRECT 28866675 ↗ — SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration
- T6INDIRECT 27388951 ↗ — Choroidal and macular thickness changes in type 1 diabetes mellitus patients without diabetic retino
- T6 35186126 ↗ — Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
- T6 27895936 ↗ — Neovascular glaucoma: a review
- T6 27769587 ↗ — Deep Retinal Layer Microvasculature Dropout Detected by the Optical Coherence Tomography Angiography
- T6INDIRECT 33270751 ↗ — Retinal changes in COVID-19 hospitalized cases
- T6INDIRECT 32735134 ↗ — Papillophlebitis in a COVID-19 patient: Inflammation and hypercoagulable state
- T6INDIRECT 33249111 ↗ — Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19:
- T6INDIRECT 25775251 ↗ — The ophthalmic branch of the Gutenberg Health Study: study design, cohort profile and self-reported
- T6INDIRECT 37886027 ↗ — GEMA 5.3. Spanish Guideline on the Management of Asthma
- T6INDIRECT 33961108 ↗ — Reduced macular vessel density in COVID-19 patients with and without associated thrombotic events us
- T6 34830247 ↗ — Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
- T6 30967901 ↗ — Risks and risk management in modern multiple sclerosis immunotherapeutic treatment
- T6 34370174 ↗ — Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches
- T6 33372616 ↗ — French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa
- T6 22117835 ↗ — Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary
- T6 25387009 ↗ — Ophthalmological features of Parkinson disease
T2 — RCT in related condition
MCAS
17 sources
- T6INDIRECT 41251748 ↗ — Efficacy and safety of different doses of ligelizumab in patients with chronic spontaneous urticaria
- T6INDIRECT 37572360 ↗ — Interventions for bullous pemphigoid
- T2 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6 33685604 ↗ — Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
- T6 38101757 ↗ — Feast for thought: A comprehensive review of food allergy 2021-2023
- T6 26621973 ↗ — Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge
- T6 27864548 ↗ — From IgE to Omalizumab
- T6INDIRECT 28097159 ↗ — IgE-Related Chronic Diseases and Anti-IgE-Based Treatments
- T6INDIRECT 31636640 ↗ — The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid
- T6INDIRECT 30882368 ↗ — The use of biologics for immune modulation in allergic disease
- T6INDIRECT 33628747 ↗ — Anti-IgE for the Treatment of Chronic Urticaria
- T6INDIRECT 28078079 ↗ — Looking forward to new targeted treatments for chronic spontaneous urticaria
- T6INDIRECT 31494233 ↗ — Current and emerging treatments for chronic spontaneous urticaria
- T6INDIRECT 34456900 ↗ — Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy
- T6INDIRECT 31172716 ↗ — Emerging Therapies in Chronic Spontaneous Urticaria
- T6 32086776 ↗ — The Role of Mast Cells in IgE-Independent Lung Diseases
- T6 36652536 ↗ — Allergy: Mechanistic insights into new methods of prevention and therapy
T2 — RCT in related condition
MCAS
27 sources
- T6INDIRECT 40696933 ↗ — Manual acupuncture for the treatment of chronic spontaneous urticaria: a systematic review and meta-
- T6INDIRECT 40663028 ↗ — Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic ur
- T6INDIRECT 40520797 ↗ — Clinical efficacy and safety of acupuncture in the treatment for chronic spontaneous urticaria: a sy
- T2 36096203 ↗ — Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneo
- T2 40043237 ↗ — Remibrutinib in Chronic Spontaneous Urticaria
- T6INDIRECT 40266575 ↗ — Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomi
- T6INDIRECT 38308655 ↗ — Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a
- T2 41115533 ↗ — Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
- T6 35667749 ↗ — Autoimmune chronic spontaneous urticaria
- T6 32224621 ↗ — Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020
- T6INDIRECT 38492772 ↗ — Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
- T6INDIRECT 37386330 ↗ — Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
- T6INDIRECT 39028396 ↗ — New insights into chronic inducible urticaria
- T6INDIRECT 40532792 ↗ — Current and future landscape of Bruton tyrosine kinase inhibitors in allergy
- T6INDIRECT 39598410 ↗ — Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
- T6INDIRECT 36776192 ↗ — Biologicals in Treatment of Chronic Urticaria: A Narrative Review
- T6INDIRECT 35956071 ↗ — Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease
- T6INDIRECT 39932658 ↗ — Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dich
- T6 36183125 ↗ — BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms
- T6 38101757 ↗ — Feast for thought: A comprehensive review of food allergy 2021-2023
- T6 36251242 ↗ — New Mechanistic Advances in FcεRI-Mast Cell-Mediated Allergic Signaling
- T6 32401033 ↗ — A Fast and Clean BTK Inhibitor
- T6 38630620 ↗ — Mast cells: a novel therapeutic avenue for cardiovascular diseases?
- T6 36430941 ↗ — Human Lung Mast Cells: Therapeutic Implications in Asthma
- T6 34778053 ↗ — Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Ma
- T6 35175630 ↗ — Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatologic
- T6 38141832 ↗ — BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria
T2 — RCT in related condition
MCAS
20 sources
- T6INDIRECT 37572360 ↗ — Interventions for bullous pemphigoid
- T6INDIRECT 40520797 ↗ — Clinical efficacy and safety of acupuncture in the treatment for chronic spontaneous urticaria: a sy
- T2 40266575 ↗ — Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomi
- T6 36183125 ↗ — BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms
- T6 37188939 ↗ — Protein kinases: drug targets for immunological disorders
- T6 35175630 ↗ — Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatologic
- T6 38474348 ↗ — Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons
- T6 33674445 ↗ — Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibi
- T6 40838448 ↗ — Immunosuppressants for IgG4-related disease
- T6INDIRECT 38492772 ↗ — Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
- T6INDIRECT 37386330 ↗ — Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
- T6INDIRECT 39028396 ↗ — New insights into chronic inducible urticaria
- T6INDIRECT 40532792 ↗ — Current and future landscape of Bruton tyrosine kinase inhibitors in allergy
- T6INDIRECT 39598410 ↗ — Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
- T6INDIRECT 35956071 ↗ — Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease
- T6INDIRECT 39932658 ↗ — Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dich
- T6 36903645 ↗ — Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinica
- T6 35290608 ↗ — Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4
- T6 36140335 ↗ — The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target
- T6 38141832 ↗ — BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria
T2 — RCT in related condition
MCAS
22 sources
- T2 20548096 ↗ — Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-
- T6INDIRECT 34904799 ↗ — Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
- T2 30901302 ↗ — Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristin
- T6INDIRECT 36542826 ↗ — Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the p
- T2 30184451 ↗ — Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- T2 30811293 ↗ — First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Ben
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T6INDIRECT 25842160 ↗ — Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 32934330 ↗ — Exploring the NK cell platform for cancer immunotherapy
- T6INDIRECT 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6INDIRECT 28242845 ↗ — Focal Segmental Glomerulosclerosis
- T6INDIRECT 33649022 ↗ — Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management
- T6INDIRECT 32107531 ↗ — Pediatric hemophagocytic lymphohistiocytosis
- T6INDIRECT 32106302 ↗ — Overview of Castleman disease
- T6INDIRECT 33219338 ↗ — Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease
- T4 29915719 ↗ — Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy
- T6INDIRECT 27777266 ↗ — A Proposal for a Serology-Based Approach to Membranous Nephropathy
- T6 33046850 ↗ — Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 28550082 ↗ — Primary Membranous Nephropathy
- T6 33657296 ↗ — Diffuse Large B-Cell Lymphoma
T2 — RCT in related condition
RegisteredMCAS
37 sources
- T2REGISTERED-ONLY NCT07655375 ↗ — Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
- T6INDIRECT 34470661 ↗ — Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histologica
- T6INDIRECT 24101698 ↗ — Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes
- T6INDIRECT 9516894 ↗ — Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm
- T6INDIRECT 29228964 ↗ — Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and card
- T6INDIRECT 23936562 ↗ — Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine pr
- T6INDIRECT 30914378 ↗ — Integrative analysis of the intestinal metabolome of childhood asthma
- T6INDIRECT 28342911 ↗ — Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis
- T6INDIRECT 33147277 ↗ — Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myelom
- T6INDIRECT 25527564 ↗ — Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder
- T6INDIRECT 33675817 ↗ — Peanut diversity and specific activity are the dominant IgE characteristics for effector cell activa
- T6 34248921 ↗ — Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Con
- T6 34308300 ↗ — Characterizing long COVID in an international cohort: 7 months of symptoms and their impact
- T6INDIRECT 26459294 ↗ — Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highligh
- T6INDIRECT 26110030 ↗ — Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid:
a systematic review
- T6INDIRECT 21829582 ↗ — Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and re
- T6INDIRECT 30145102 ↗ — The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gu
- T6INDIRECT 16621965 ↗ — Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to trea
- T6INDIRECT 25842160 ↗ — Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a
- T6INDIRECT 28924229 ↗ — Variations in oral microbiota associated with oral cancer
- T6INDIRECT 18765957 ↗ — Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North Ame
- T6INDIRECT 14557297 ↗ — Current perspectives on ophthalmic mycoses
- T6INDIRECT 28401256 ↗ — Immune-mediated cytokine storm and its role in severe dengue
- T6INDIRECT 27881403 ↗ — Irritable bowel syndrome: a gut microbiota-related disorder?
- T6INDIRECT 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6INDIRECT 19010417 ↗ — Biomarkers of Alzheimer's disease
- T6INDIRECT 27863252 ↗ — The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease
- T6INDIRECT 22552007 ↗ — EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal,
- T6INDIRECT 32010645 ↗ — The Oral Microbiota May Have Influence on Oral Cancer
- T6 21304480 ↗ — Epidemiology of Alzheimer disease
- T6 31110428 ↗ — Oral microbiome: Unveiling the fundamentals
- T6 32473127 ↗ — Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed
- T6 10987697 ↗ — Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease
- T6 32404436 ↗ — TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
- T6 32470396 ↗ — Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alteratio
- T6 15326289 ↗ — Identification and proteomic profiling of exosomes in human urine
- T6 22698087 ↗ — Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils
T2 — RCT in related condition
MCAS
21 sources
- T6INDIRECT 29650949 ↗ — Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
- T6INDIRECT 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6INDIRECT 28435464 ↗ — Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of F
- T2 30654196 ↗ — Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a D
- T6INDIRECT 39785096 ↗ — CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Bl
- T6INDIRECT 23041624 ↗ — T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection
- T6INDIRECT 24176117 ↗ — A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic pa
- T6INDIRECT 17765756 ↗ — Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
- T6INDIRECT 25789989 ↗ — A pilot study of omalizumab in eosinophilic esophagitis
- T6 18650915 ↗ — The development of allergic inflammation
- T6INDIRECT 25754717 ↗ — Biologic therapies targeting eosinophils: current status and future prospects
- T6INDIRECT 31636640 ↗ — The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid
- T6INDIRECT 28725969 ↗ — Mastocytosis: from a Molecular Point of View
- T6INDIRECT 32421085 ↗ — Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in
- T6INDIRECT 27334777 ↗ — Guideline of Chronic Urticaria Beyond
- T6INDIRECT 35987486 ↗ — Safety of Biologics for Atopic Diseases During Pregnancy
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6INDIRECT 24532966 ↗ — Omalizumab, an anti-immunoglobulin E antibody: state of the art
- T6 24531552 ↗ — Bitter and sweet taste receptors regulate human upper respiratory innate immunity
- T6 33811184 ↗ — SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-de
- T6 32224621 ↗ — Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020
avapritinib (KIT/PDGFRA inhibitor)
T2
T2 — RCT in related condition
MCAS
23 sources
- T2 35114819 ↗ — Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic
- T2 38320129 ↗ — Avapritinib versus Placebo in Indolent Systemic Mastocytosis
- T2 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6 32929378 ↗ — Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precisi
- T6 37849038 ↗ — Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
- T6 36130297 ↗ — Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
- T6 34873347 ↗ — Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
- T6 32804590 ↗ — Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor
- T4 35790816 ↗ — Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocyt
- T6INDIRECT 34322383 ↗ — Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gast
- T6INDIRECT 31372066 ↗ — Novel approaches to treating advanced systemic mastocytosis
- T6INDIRECT 32462367 ↗ — Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates
- T6INDIRECT 36980652 ↗ — Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
- T6INDIRECT 33804174 ↗ — Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
- T6INDIRECT 38851398 ↗ — Mast cell activation syndrome: Current understanding and research needs
- T6INDIRECT 35544644 ↗ — CancerVar: An artificial intelligence-empowered platform for clinical interpretation of somatic muta
- T6 39138146 ↗ — Therapeutic advances of targeting receptor tyrosine kinases in cancer
- T6 36254250 ↗ — Small molecule inhibitors targeting the cancers
- T6 36849435 ↗ — Molecular and functional imaging in cancer-targeted therapy: current applications and future directi
- T6 35217782 ↗ — New treatment strategies for advanced-stage gastrointestinal stromal tumours
- T6 30884251 ↗ — Recent advances in our understanding of mast cell activation - or should it be mast cell mediator di
benralizumab (anti-IL-5Rα)
T2
T2 — RCT in related condition
MCAS
27 sources
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 35316551 ↗ — A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendat
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 37658939 ↗ — Vernal Keratoconjunctivitis: A Systematic Review
- T2 30943337 ↗ — Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome
- T2 30658649 ↗ — Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseas
- T2 38367194 ↗ — Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: resu
- T2 32997916 ↗ — Benralizumab for Chronic Spontaneous Urticaria
- T6 34824210 ↗ — The JAK/STAT signaling pathway: from bench to clinic
- T6 28689842 ↗ — Asthma Exacerbations: Pathogenesis, Prevention, and Treatment
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 34519063 ↗ — Advances and highlights in biomarkers of allergic diseases
- T6INDIRECT 29682504 ↗ — Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
- T6INDIRECT 31836530 ↗ — Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagiti
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 35496822 ↗ — The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associate
- T6INDIRECT 25754717 ↗ — Biologic therapies targeting eosinophils: current status and future prospects
- T6INDIRECT 31239747 ↗ — Eosinophilic gastroenteritis: diagnosis and clinical perspectives
- T6 28713812 ↗ — The Biology of Eosinophils and Their Role in Asthma
- T6 28910134 ↗ — Eosinophilic and Noneosinophilic Asthma
- T6 29733746 ↗ — The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced anti
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
- T6 36928371 ↗ — The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
- T6 32893900 ↗ — Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma
- T6 34473358 ↗ — Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical fin
- T6 35923421 ↗ — Type 2 inflammation in asthma and other airway diseases
bilastine (H1 antihistamine)
T2
T2 — RCT in related condition
MCAS
21 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 33665200 ↗ — Skin Manifestations in COVID-19 Patients: Are They Indicators for Disease Severity? A Systematic Rev
- T6INDIRECT 35316551 ↗ — A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendat
- T6INDIRECT 32986289 ↗ — Management of urticaria in COVID-19 patients: A systematic review
- T6INDIRECT 33030434 ↗ — Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Revie
- T6INDIRECT 24472058 ↗ — Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chr
- T2 26918853 ↗ — Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic disea
- T2 32618048 ↗ — Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment
- T6INDIRECT 39785096 ↗ — CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Bl
- T6 22035879 ↗ — Histamine and H1-antihistamines: celebrating a century of progress
- T6INDIRECT 29527019 ↗ — Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23282382 ↗ — Diagnosis and treatment of urticaria and angioedema: a worldwide perspective
- T6INDIRECT 23282578 ↗ — H1 antihistamines: current status and future directions
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 35463011 ↗ — Allergic Rhinitis: A Clinical and Pathophysiological Overview
- T6 30805711 ↗ — Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development
- T6 37601647 ↗ — Immunologic, genetic, and ecological interplay of factors involved in allergic diseases
- T6 35879928 ↗ — Current and Future Strategies for the Diagnosis and Treatment of the Alpha-Gal Syndrome (AGS)
- T6 30924425 ↗ — Chronic Urticaria: An Overview of Treatment and Recent Patents
canakinumab (anti-IL-1β)
T2
T2 — RCT in related condition
MCAS
25 sources
- T6INDIRECT 34394107 ↗ — Serum C-Reactive Protein and Periodontitis: A Systematic Review and Meta-Analysis
- T6INDIRECT 35359659 ↗ — Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinica
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 34431983 ↗ — Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
- T6INDIRECT 29141858 ↗ — Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recen
- T6INDIRECT 22875601 ↗ — Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficac
- T2 32827729 ↗ — Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Ur
- T2 23087179 ↗ — Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial
- T6INDIRECT 27663070 ↗ — Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/
- T6INDIRECT 34096620 ↗ — Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman d
- T6INDIRECT 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6INDIRECT 33867315 ↗ — The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives
- T6INDIRECT 35606650 ↗ — Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treat
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 36941354 ↗ — Clonal haematopoiesis and dysregulation of the immune system
- T6INDIRECT 25905009 ↗ — Schnitzler's syndrome: lessons from 281 cases
- T6INDIRECT 33073244 ↗ — Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?
- T6INDIRECT 25758134 ↗ — Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
- T6 26121197 ↗ — Inflammasomes: mechanism of action, role in disease, and therapeutics
- T6 25625584 ↗ — NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflamm
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 30774631 ↗ — The Immunology of Macrophage Activation Syndrome
- T6 30042333 ↗ — Interleukin-1 Beta-A Friend or Foe in Malignancies?
- T6 34298011 ↗ — Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, ch
- T6 30670444 ↗ — The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
T2 — RCT in related condition
MCAS
25 sources
- T6INDIRECT 31981369 ↗ — Interventions for chronic pruritus of unknown origin
- T6INDIRECT 41408255 ↗ — Effectiveness of 0.1% triamcinolone acetonide compared with those of other therapies for minor recur
- T6INDIRECT 39067455 ↗ — The role of fibrosis in endometriosis: a systematic review
- T6INDIRECT 36742321 ↗ — Dupilumab for the treatment of prurigo nodularis: A systematic review
- T6INDIRECT 39899062 ↗ — The Effects of Cannabinoids on Ischemic Stroke-Associated Neuroinflammation: A Systematic Review
- T6INDIRECT 40873582 ↗ — The role of TGF-β superfamily in endometriosis: a systematic review
- T6INDIRECT 32678452 ↗ — Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial
- T6INDIRECT 36837393 ↗ — Hemp Seed Oil in Association with β-Caryophyllene, Myrcene and Ginger Extract as a Nutraceutical Int
- T6INDIRECT 41730291 ↗ — Colchicine in patients with chronic inflammatory cardiomyopathy: rationale and design of the CMP-MYT
- T2 41635790 ↗ — Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in
- T6INDIRECT 34625019 ↗ — Inflammatory complications of CGRP monoclonal antibodies: a case series
- T6INDIRECT 32316328 ↗ — A Guide to Targeting the Endocannabinoid System in Drug Design
- T6INDIRECT 34512404 ↗ — A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Di
- T6INDIRECT 31396087 ↗ — Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease
- T6INDIRECT 35102560 ↗ — Cannabis-related allergies: An international overview and consensus recommendations
- T6INDIRECT 35215320 ↗ — Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
- T6INDIRECT 33810493 ↗ — Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic P
- T6 25407511 ↗ — Intestinal permeability--a new target for disease prevention and therapy
- T6 33046850 ↗ — Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
- T6 25796370 ↗ — Endocannabinoid signaling at the periphery: 50 years after THC
- T6 33718398 ↗ — Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review
- T6 21420431 ↗ — Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system
- T6 36928371 ↗ — The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
- T6 21062421 ↗ — TRPV channels and vascular function
- T6 7724569 ↗ — Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and
desloratadine (H1 antihistamine)
T2
T2 — RCT in related condition
MCAS
24 sources
- T6INDIRECT 27237730 ↗ — Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic rev
- T6INDIRECT 30427977 ↗ — Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic
- T6INDIRECT 19001265 ↗ — Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized
- T6INDIRECT 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T2 20226302 ↗ — The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficu
- T6INDIRECT 15947280 ↗ — Inflammatory basis of exercise-induced bronchoconstriction
- T6INDIRECT 34750553 ↗ — Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized p
- T2 11277962 ↗ — Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomiz
- T6INDIRECT 10831005 ↗ — Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria
- T6INDIRECT 28160338 ↗ — H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first result
- T6INDIRECT 15577865 ↗ — Rhinosinusitis: establishing definitions for clinical research and patient care
- T6INDIRECT 33821570 ↗ — Delivery of oligonucleotide-based therapeutics: challenges and opportunities
- T6INDIRECT 15577816 ↗ — Rhinosinusitis: Establishing definitions for clinical research and patient care
- T6INDIRECT 29431216 ↗ — Mast cell-neural interactions contribute to pain and itch
- T6INDIRECT 37630231 ↗ — Malondialdehyde as a Potential Oxidative Stress Marker for Allergy-Oriented Diseases: An Update
- T6INDIRECT 27861988 ↗ — Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6 23334570 ↗ — A review on anti-inflammatory activity of monoterpenes
- T6 21460831 ↗ — TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch
- T6 14660743 ↗ — Mast cells are required for experimental oral allergen-induced diarrhea
- T6 31027996 ↗ — Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic I
- T6 21134576 ↗ — Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAI
- T6 23268454 ↗ — World allergy organization guidelines for the assessment and management of anaphylaxis
T2 — RCT in related condition
MCAS
26 sources
- T6 NCT04681105 ↗ — Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malig
- T6 32678530 ↗ — Dexamethasone in Hospitalized Patients with Covid-19.
- T6INDIRECT 37056675 ↗ — The crucial role and mechanism of insulin resistance in metabolic disease
- T6INDIRECT 33937212 ↗ — Foreign Body Reaction to Implanted Biomaterials and Its Impact in Nerve Neuroprosthetics
- T6INDIRECT 19960229 ↗ — The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review
- T6INDIRECT 36542826 ↗ — Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the p
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T6INDIRECT 25042748 ↗ — Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a
- T2 8648382 ↗ — Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma
- T6INDIRECT 22733017 ↗ — Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 33657296 ↗ — Diffuse Large B-Cell Lymphoma
- T6INDIRECT 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6INDIRECT 32107531 ↗ — Pediatric hemophagocytic lymphohistiocytosis
- T6INDIRECT 14557297 ↗ — Current perspectives on ophthalmic mycoses
- T6INDIRECT 34039409 ↗ — The landscape of bispecific T cell engager in cancer treatment
- T6INDIRECT 25279127 ↗ — Dry eye: an inflammatory ocular disease
- T6INDIRECT 32184554 ↗ — The Evolving Treatment of Diabetic Retinopathy
- T6INDIRECT 33867315 ↗ — The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives
- T6INDIRECT 24813302 ↗ — Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of a
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6 21766791 ↗ — Resolvins and protectins in inflammation resolution
- T6 29411111 ↗ — Functional morphology of the blood-brain barrier in health and disease
- T6 25686754 ↗ — The role of inflammation in perinatal brain injury
- T6 19601838 ↗ — The roles of antimicrobial peptides in innate host defense
- T6 15109499 ↗ — Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal
dupilumab (anti-IL-4/IL-13)
T2
T2 — RCT in related condition
MCAS
26 sources
- T6INDIRECT 26459294 ↗ — Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highligh
- T2 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 35275399 ↗ — Strategies for using topical corticosteroids in children and adults with eczema
- T6INDIRECT 35316551 ↗ — A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendat
- T6INDIRECT 37658939 ↗ — Vernal Keratoconjunctivitis: A Systematic Review
- T6INDIRECT 29650949 ↗ — Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
- T2 38431226 ↗ — Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double
- T2 33611847 ↗ — Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis w
- T6 34824210 ↗ — The JAK/STAT signaling pathway: from bench to clinic
- T6 27795547 ↗ — Food allergy: immune mechanisms, diagnosis and immunotherapy
- T6INDIRECT 34519063 ↗ — Advances and highlights in biomarkers of allergic diseases
- T6INDIRECT 29114938 ↗ — Immune response patterns in non-communicable inflammatory skin diseases
- T6INDIRECT 29374516 ↗ — The vicious cycle of itch and anxiety
- T6INDIRECT 29259713 ↗ — The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and prurit
- T6INDIRECT 31836530 ↗ — Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagiti
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 35373533 ↗ — International consensus statement on allergy and rhinology: Olfaction
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6 28910134 ↗ — Eosinophilic and Noneosinophilic Asthma
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 31869278 ↗ — Physiology and Pathophysiology of Itch
- T6 36428114 ↗ — Novel insights into atopic dermatitis
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
- T6 34473358 ↗ — Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical fin
- T6 35923421 ↗ — Type 2 inflammation in asthma and other airway diseases
- T6 31838750 ↗ — Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit t
fexofenadine (H1 antihistamine)
T2
T2 — RCT in related condition
MCAS
20 sources
- T6INDIRECT 35742951 ↗ — IL-31: State of the Art for an Inflammation-Oriented Interleukin
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 33206207 ↗ — Histamine receptors and COVID-19
- T2 10831005 ↗ — Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria
- T2 10417497 ↗ — A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and prom
- T6INDIRECT 24472058 ↗ — Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chr
- T6INDIRECT 12968983 ↗ — Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the ski
- T6INDIRECT 17765756 ↗ — Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
- T6 26779180 ↗ — Mast Cell: A Multi-Functional Master Cell
- T6 29949830 ↗ — Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
- T6INDIRECT 32571129 ↗ — Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients
- T6INDIRECT 26755686 ↗ — Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside
- T6INDIRECT 24262698 ↗ — Mastocytosis
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6INDIRECT 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 33105588 ↗ — Perivascular Inflammation in Pulmonary Arterial Hypertension
- T6 23734637 ↗ — The role of histamine in neurogenic inflammation
imatinib (tyrosine kinase inhibitor)
T2
T2 — RCT in related condition
MCAS
22 sources
- T2 28514613 ↗ — KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
- T6INDIRECT 30943337 ↗ — Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome
- T6INDIRECT 28069279 ↗ — Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placeb
- T2 12932387 ↗ — Imatinib for systemic mast-cell disease
- T6INDIRECT 31922567 ↗ — The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
- T6 35732831 ↗ — The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid
- T6 18483217 ↗ — Role of platelet-derived growth factors in physiology and medicine
- T6 25810047 ↗ — Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma
- T6 22834835 ↗ — Functions of S100 proteins
- T6 25266247 ↗ — Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task fo
- T6INDIRECT 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 18684881 ↗ — Mast cells and mastocytosis
- T6INDIRECT 29431216 ↗ — Mast cell-neural interactions contribute to pain and itch
- T6INDIRECT 34684008 ↗ — Improving Curcumin Bioavailability: Current Strategies and Future Perspectives
- T6INDIRECT 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6INDIRECT 28885612 ↗ — Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight int
- T6INDIRECT 22504184 ↗ — Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 20176269 ↗ — IgE, mast cells, basophils, and eosinophils
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6 18982161 ↗ — The cytokine network in asthma and chronic obstructive pulmonary disease
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
ketotifen (mast cell stabiliser)
T2
T2 — RCT in related condition
MCAS
24 sources
- T6INDIRECT 33283264 ↗ — Interventions for itch in people with advanced chronic kidney disease
- T6INDIRECT 33239034 ↗ — Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review
- T6INDIRECT 37658939 ↗ — Vernal Keratoconjunctivitis: A Systematic Review
- T2 20650926 ↗ — The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal sympt
- T6INDIRECT 19491822 ↗ — The role of mast cell stabilization in treatment of postoperative ileus: a pilot study
- T6INDIRECT 2972308 ↗ — The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronch
- T6INDIRECT 17765756 ↗ — Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
- T2 2654254 ↗ — A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment
- T6INDIRECT 2451929 ↗ — The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chlori
- T6 29984112 ↗ — Immune Regulation of Skin Wound Healing: Mechanisms and Novel Therapeutic Targets
- T6INDIRECT 30813280 ↗ — Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barr
- T6INDIRECT 32571129 ↗ — Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients
- T6INDIRECT 26690128 ↗ — Mast Cell-Mediated Mechanisms of Nociception
- T6INDIRECT 31256161 ↗ — Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activat
- T6INDIRECT 26755686 ↗ — Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside
- T6INDIRECT 33307116 ↗ — The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspir
- T6INDIRECT 27867684 ↗ — Eosinophilic gastroenteritis: Approach to diagnosis and management
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6 14760748 ↗ — Key role of mast cells and their major secretory products in inflammatory bowel disease
- T6 21908429 ↗ — Mast cell modulation of the vascular and lymphatic endothelium
- T6 30825305 ↗ — Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities
- T6 30744042 ↗ — Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis
- T6 25517090 ↗ — Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions
- T6 17005763 ↗ — Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum
levocetirizine (H1 antihistamine)
T2
T2 — RCT in related condition
MCAS
21 sources
- T6INDIRECT 33206207 ↗ — Histamine receptors and COVID-19
- T6INDIRECT 33030434 ↗ — Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Revie
- T2 20226302 ↗ — The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficu
- T2 16445787 ↗ — Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo
- T6INDIRECT 32429063 ↗ — Probiotic NVP-1703 Alleviates Allergic Rhinitis by Inducing IL-10 Expression: A Four-week Clinical T
- T6INDIRECT 24472058 ↗ — Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chr
- T6INDIRECT 18480923 ↗ — Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled t
- T2 12968983 ↗ — Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the ski
- T6INDIRECT 20406224 ↗ — No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough
- T6INDIRECT 15298570 ↗ — Interactions between eotaxin, histamine and mast cells in early microvascular events associated with
- T6INDIRECT 32571129 ↗ — Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients
- T6INDIRECT 35373533 ↗ — International consensus statement on allergy and rhinology: Olfaction
- T6INDIRECT 20426711 ↗ — Therapy of pruritus
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 22410181 ↗ — Diagnostic tools in Rhinology EAACI position paper
- T6INDIRECT 23282382 ↗ — Diagnosis and treatment of urticaria and angioedema: a worldwide perspective
- T6INDIRECT 23282578 ↗ — H1 antihistamines: current status and future directions
- T6 29949830 ↗ — Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 33452689 ↗ — EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19
loratadine (H1 antihistamine)
T2
T2 — RCT in related condition
MCAS
22 sources
- T6INDIRECT 33283264 ↗ — Interventions for itch in people with advanced chronic kidney disease
- T2 20226302 ↗ — The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficu
- T6INDIRECT 15947280 ↗ — Inflammatory basis of exercise-induced bronchoconstriction
- T6INDIRECT 28435464 ↗ — Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of F
- T6INDIRECT 34750553 ↗ — Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized p
- T2 11277962 ↗ — Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomiz
- T2 15347373 ↗ — Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, d
- T2 10417497 ↗ — A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and prom
- T6INDIRECT 28342911 ↗ — Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis
- T6INDIRECT 17765756 ↗ — Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
- T6INDIRECT 15577865 ↗ — Rhinosinusitis: establishing definitions for clinical research and patient care
- T6INDIRECT 15577816 ↗ — Rhinosinusitis: Establishing definitions for clinical research and patient care
- T6INDIRECT 29431216 ↗ — Mast cell-neural interactions contribute to pain and itch
- T6INDIRECT 35964548 ↗ — Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- T6INDIRECT 20426711 ↗ — Therapy of pruritus
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23282382 ↗ — Diagnosis and treatment of urticaria and angioedema: a worldwide perspective
- T6 15972446 ↗ — Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V
- T6 29949830 ↗ — Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 21908429 ↗ — Mast cell modulation of the vascular and lymphatic endothelium
masitinib (KIT inhibitor)
T2
T2 — RCT in related condition
MCAS
23 sources
- T2 28069279 ↗ — Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placeb
- T2 22691628 ↗ — Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
- T2 25858497 ↗ — A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of a
- T6INDIRECT 29194765 ↗ — c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated wi
- T6INDIRECT 24407160 ↗ — Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic
- T6INDIRECT 35579040 ↗ — Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-hig
- T6 39174535 ↗ — Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strateg
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6 29618972 ↗ — An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
- T6 31256327 ↗ — Role of Mast Cells in Shaping the Tumor Microenvironment
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 24262698 ↗ — Mastocytosis
- T6INDIRECT 27132234 ↗ — Pharmacological treatment options for mast cell activation disease
- T6INDIRECT 28725969 ↗ — Mastocytosis: from a Molecular Point of View
- T6INDIRECT 23181448 ↗ — Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
- T6INDIRECT 31372066 ↗ — Novel approaches to treating advanced systemic mastocytosis
- T6INDIRECT 24044484 ↗ — Mastocytosis: update on pharmacotherapy and future directions
- T6INDIRECT 34893494 ↗ — Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
- T6 29925402 ↗ — Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
- T6 33340024 ↗ — Improving clinical trial outcomes in amyotrophic lateral sclerosis
- T6 32929378 ↗ — Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precisi
- T6 36254250 ↗ — Small molecule inhibitors targeting the cancers
- T6 27536065 ↗ — Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
midostaurin (KIT inhibitor)
T2
T2 — RCT in related condition
MCAS
21 sources
- T2 28644114 ↗ — Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- T2 24085261 ↗ — Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers
- T2 24839948 ↗ — Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between
- T2 32437738 ↗ — Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6 26679767 ↗ — Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive
- T6 30713991 ↗ — The growing role of precision and personalized medicine for cancer treatment
- T6 27355533 ↗ — Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
- T6 34873347 ↗ — Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 34774343 ↗ — A review of FLT3 inhibitors in acute myeloid leukemia
- T4 29487059 ↗ — Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 24262698 ↗ — Mastocytosis
- T6INDIRECT 27132234 ↗ — Pharmacological treatment options for mast cell activation disease
- T6INDIRECT 28725969 ↗ — Mastocytosis: from a Molecular Point of View
- T6 24359404 ↗ — Targeting the PDGF signaling pathway in tumor treatment
- T6 37143582 ↗ — Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, an
- T6 25650093 ↗ — KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on
- T6 27536065 ↗ — Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
T2 — RCT in related condition
MCAS
23 sources
- T6 NCT00006251 ↗ — Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by C
- T6 NCT00014235 ↗ — Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transpla
- T6 NCT00118352 ↗ — Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophen
- T6 NCT00112593 ↗ — Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and M
- T6INDIRECT 22972085 ↗ — Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)
- T6INDIRECT 36578492 ↗ — Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A sy
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 26092582 ↗ — Immunoglobulin G4-related diseases in the head and neck: a systematic review
- T6INDIRECT 20431041 ↗ — Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and l
- T6INDIRECT 20634300 ↗ — Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy
- T6INDIRECT 30879003 ↗ — Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontan
- T2 17040448 ↗ — Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not res
- T6 28550082 ↗ — Primary Membranous Nephropathy
- T6 28242845 ↗ — Focal Segmental Glomerulosclerosis
- T6INDIRECT 30558872 ↗ — Antibiotic allergy
- T6INDIRECT 28139263 ↗ — JAK inhibitors in dermatology: The promise of a new drug class
- T6INDIRECT 27777266 ↗ — A Proposal for a Serology-Based Approach to Membranous Nephropathy
- T6INDIRECT 26907530 ↗ — Mechanisms of Disease: Pemphigus and Bullous Pemphigoid
- T6INDIRECT 24366648 ↗ — Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6 35504917 ↗ — COVID-19 vaccine development: milestones, lessons and prospects
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
- T6 25433021 ↗ — Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardio
T2 — RCT in related condition
MCAS
27 sources
- T2 11483846 ↗ — Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
- T2 26581915 ↗ — A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy
- T2 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T2 21636116 ↗ — Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyrope
- T6INDIRECT 29650949 ↗ — Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
- T6INDIRECT 28514613 ↗ — KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
- T6INDIRECT 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6INDIRECT 25042748 ↗ — Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a
- T2 24176117 ↗ — A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic pa
- T2 18774392 ↗ — Treatment of chronic autoimmune urticaria with omalizumab
- T6INDIRECT 26907530 ↗ — Mechanisms of Disease: Pemphigus and Bullous Pemphigoid
- T6INDIRECT 37630231 ↗ — Malondialdehyde as a Potential Oxidative Stress Marker for Allergy-Oriented Diseases: An Update
- T6INDIRECT 32436290 ↗ — EAACI Allergen Immunotherapy User's Guide
- T4 27861988 ↗ — Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
- T6INDIRECT 34519063 ↗ — Advances and highlights in biomarkers of allergic diseases
- T6INDIRECT 25109885 ↗ — Advances in clinical management of eosinophilic esophagitis
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6 22561833 ↗ — IgE and mast cells in allergic disease
- T6 18650915 ↗ — The development of allergic inflammation
- T6 20176269 ↗ — IgE, mast cells, basophils, and eosinophils
- T6 27795547 ↗ — Food allergy: immune mechanisms, diagnosis and immunotherapy
- T6 28780941 ↗ — The pathophysiology of anaphylaxis
- T6 25452755 ↗ — Mast cell mediators: their differential release and the secretory pathways involved
- T6 19828304 ↗ — Mast cells in atopic dermatitis
- T6 23587334 ↗ — Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of A
- T6 23268454 ↗ — World allergy organization guidelines for the assessment and management of anaphylaxis
ranitidine (H2 antihistamine)
T2
T2 — RCT in related condition
MCASPOTS
46 sources
- T6INDIRECT 31025714 ↗ — Interventions for hand eczema
- T6INDIRECT 35268051 ↗ — Vitamin D Supplementation and Sleep: A Systematic Review and Meta-Analysis of Intervention Studies
- T6INDIRECT 22419335 ↗ — Histamine H2-receptor antagonists for urticaria
- T6INDIRECT 33206207 ↗ — Histamine receptors and COVID-19
- T6INDIRECT 33080623 ↗ — Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multi
- T2 2878811 ↗ — Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 4
- T6INDIRECT 24507460 ↗ — Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study
- T6INDIRECT 8676090 ↗ — Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia
- T2 6150641 ↗ — Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patient
- T6 30150993 ↗ — The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hu
- T6INDIRECT 29926477 ↗ — Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent
- T6INDIRECT 29694674 ↗ — Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent
- T6INDIRECT 36190739 ↗ — Pharmacological interventions for prevention of weight gain in people with schizophrenia
- T6INDIRECT 28893208 ↗ — Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients
- T6INDIRECT 28655357 ↗ — Drug-related problems and medication reviews among old people with dementia
- T6INDIRECT 26461064 ↗ — Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped
- T6INDIRECT 23179472 ↗ — Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compare
- T6INDIRECT 10646881 ↗ — Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy
- T6 16678566 ↗ — Childhood functional gastrointestinal disorders: child/adolescent
- T6 37139824 ↗ — American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medicatio
- T6INDIRECT 34684008 ↗ — Improving Curcumin Bioavailability: Current Strategies and Future Perspectives
- T6INDIRECT 21668033 ↗ — Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations
- T6INDIRECT 31640115 ↗ — Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility
- T6INDIRECT 35964548 ↗ — Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6INDIRECT 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 31739596 ↗ — Therapeutic Potential of α- and β-Pinene: A Miracle Gift of Nature
- T6 23476052 ↗ — Idiosyncratic adverse drug reactions: current concepts
- T6 27620496 ↗ — Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral C
- T6 21134576 ↗ — Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAI
- T6 23268454 ↗ — World allergy organization guidelines for the assessment and management of anaphylaxis
- T6INDIRECT 18085482 ↗ — Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide
- T6INDIRECT 26084539 ↗ — International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
- T6INDIRECT 29796248 ↗ — Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of cloza
- T6INDIRECT 24473486 ↗ — Medications and impaired driving
- T6INDIRECT 18959359 ↗ — Early acute management in adults with spinal cord injury: a clinical practice guideline for health-c
- T6INDIRECT 29210346 ↗ — Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocer
- T6 32872533 ↗ — Ionic Liquids Toxicity-Benefits and Threats
- T6 30884251 ↗ — Recent advances in our understanding of mast cell activation - or should it be mast cell mediator di
- T6 29055040 ↗ — THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
- T6 24517644 ↗ — The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors
- T6 26650439 ↗ — The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
- T6 17608249 ↗ — Risks of combined alcohol/medication use in older adults
- T6 32785879 ↗ — A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Tran
T2 — RCT in related condition
MCAS
25 sources
- T6INDIRECT 25919144 ↗ — Interventions for rosacea
- T6INDIRECT 31749986 ↗ — Efficacy and safety of topical and systemic medications: a systematic literature review informing th
- T6INDIRECT 33283264 ↗ — Interventions for itch in people with advanced chronic kidney disease
- T6INDIRECT 31517988 ↗ — Topical cyclosporine A therapy for dry eye syndrome
- T6INDIRECT 37487610 ↗ — The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected h
- T2 26132597 ↗ — Topical tacrolimus for atopic dermatitis
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 37486733 ↗ — The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected H
- T6INDIRECT 30623408 ↗ — Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist
- T6 28293453 ↗ — An overview and management of osteoporosis
- T6INDIRECT 19560575 ↗ — Intestinal barrier function: molecular regulation and disease pathogenesis
- T6INDIRECT 25686388 ↗ — The pathophysiology, diagnosis, and treatment of dry eye disease
- T6INDIRECT 28242845 ↗ — Focal Segmental Glomerulosclerosis
- T6INDIRECT 32106302 ↗ — Overview of Castleman disease
- T6INDIRECT 27777266 ↗ — A Proposal for a Serology-Based Approach to Membranous Nephropathy
- T6INDIRECT 24766381 ↗ — Osteoporosis prevention, screening, and treatment: a review
- T6INDIRECT 25279127 ↗ — Dry eye: an inflammatory ocular disease
- T6INDIRECT 24813302 ↗ — Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of a
- T6 18982161 ↗ — The cytokine network in asthma and chronic obstructive pulmonary disease
- T6 28550082 ↗ — Primary Membranous Nephropathy
- T6 10456976 ↗ — Cytokines in asthma
- T6 35504917 ↗ — COVID-19 vaccine development: milestones, lessons and prospects
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6 25182228 ↗ — Clinician's Guide to Prevention and Treatment of Osteoporosis
tezepelumab (anti-TSLP)
T2
T2 — RCT in related condition
MCAS
22 sources
- T6INDIRECT 40696933 ↗ — Manual acupuncture for the treatment of chronic spontaneous urticaria: a systematic review and meta-
- T6INDIRECT 41934326 ↗ — Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic R
- T6INDIRECT 40663028 ↗ — Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic ur
- T6INDIRECT 40520797 ↗ — Clinical efficacy and safety of acupuncture in the treatment for chronic spontaneous urticaria: a sy
- T2 36223848 ↗ — Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to a
- T2 39956278 ↗ — Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION st
- T6 33077936 ↗ — Kinase inhibition in autoimmunity and inflammation
- T6 36964157 ↗ — Pathogenesis of allergic diseases and implications for therapeutic interventions
- T6 35923421 ↗ — Type 2 inflammation in asthma and other airway diseases
- T6 36928371 ↗ — The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
- T6INDIRECT 29259713 ↗ — The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and prurit
- T6INDIRECT 31395149 ↗ — Pruritus in allergy and immunology
- T6INDIRECT 35095572 ↗ — Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets
- T6INDIRECT 37215720 ↗ — Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment
- T6INDIRECT 30882368 ↗ — The use of biologics for immune modulation in allergic disease
- T6INDIRECT 35126131 ↗ — Biologics in Asthma: A Molecular Perspective to Precision Medicine
- T6INDIRECT 30021447 ↗ — Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
- T6 30471983 ↗ — The Itch-Scratch Cycle: A Neuroimmune Perspective
- T6 39962262 ↗ — Type 2 immunity in allergic diseases
- T6 33807098 ↗ — Pruritus as a Distinctive Feature of Type 2 Inflammation
- T6 33233866 ↗ — Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STA
- T6 29988331 ↗ — Type 2 immunity in asthma
T4 — Case series
MCAS
14 sources
- T6 NCT01231919 ↗ — MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
- T6 31608069 ↗ — Disruption of Immune Homeostasis in Human Dendritic Cells via Regulation of Autophagy and Apoptosis
- T6 33694102 ↗ — Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
- T6 36633576 ↗ — P. gingivalis Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Resp
- T6 38612585 ↗ — Oxidative Stress Induced by Cortisol in Human Platelets
- T6 32291856 ↗ — Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with hi
- T6INDIRECT 31592543 ↗ — 17th International Congress of Immunology, 19-23 October 2019, Beijing, China
- T6INDIRECT 27553392 ↗ — Oral Free Paper Sessions
- T4 PMC9049679 ↗ — Abstracts DEGRO 2022
- T4 PMC11177578 ↗ — EHA2024 Hybrid Congress
- T4 PMC9260650 ↗ — Posters
- T6 35945449 ↗ — Phospholipase D2 controls bone homeostasis by modulating M-CSF-dependent osteoclastic cell migration
- T6 33000187 ↗ — The AKT inhibitor MK2206 suppresses airway inflammation and the pro‑remodeling pathway in a TDI‑indu
- T6 26478515 ↗ — Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT p
T4 — Case series
MCAS
15 sources
- T6 NCT00719563 ↗ — American Ginseng in Treating Patients With Fatigue Caused by Cancer
- T6 24311829 ↗ — The role and place of medicinal plants in the strategies for disease prevention
- T6 34480749 ↗ — Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
- T6 27782048 ↗ — Saponins from Chinese Medicines as Anticancer Agents
- T6 24288570 ↗ — Diet and nutrition in cancer survivorship and palliative care
- T6 23717169 ↗ — The effect of Korean red ginseng on allergic inflammation in a murine model of allergic rhinitis
- T6INDIRECT 35329893 ↗ — Herb-Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements
- T6INDIRECT 41155644 ↗ — Immunomodulatory Activities of Emerging Rare Ginsenosides F1, Rg5, Rk1, Rh1, and Rg2: From Molecular
- T4 PMC5883104 ↗ — Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 201
- T4 PMC7159487 ↗ — Poster Sessions
- T4 PMC9045590 ↗ — G. ACHARI PRIZE SESSION: ORAL PRESENTATION
- T4 PMC7151902 ↗ — Veterinary Herbal Medicine: A Systems-Based Approach
- T6 34946029 ↗ — Nutraceuticals and Herbal Food Supplements for Weight Loss: Is There a Prebiotic Role in the Mechani
- T6 37416796 ↗ — Nutraceuticals as Modulators of Immune Function: A Review of Potential Therapeutic Effects
- T6 40574070 ↗ — Natural Products for Improving Soft Tissue Healing: Mechanisms, Innovations, and Clinical Potential
T4 — Case series
MCAS
14 sources
- T6INDIRECT 40520797 ↗ — Clinical efficacy and safety of acupuncture in the treatment for chronic spontaneous urticaria: a sy
- T6 38630620 ↗ — Mast cells: a novel therapeutic avenue for cardiovascular diseases?
- T6 39028396 ↗ — New insights into chronic inducible urticaria
- T6 40074986 ↗ — Update on the Treatment of Chronic Spontaneous Urticaria
- T6 39598410 ↗ — Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
- T6 37897679 ↗ — Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development
- T6INDIRECT 40845419 ↗ — Chronic spontaneous urticaria: update on pathogenesis and therapeutic implications
- T6INDIRECT 41809769 ↗ — Treatments and Targets to Achieve Disease Control in Chronic Spontaneous Urticaria: Current and Emer
- T6INDIRECT 41410910 ↗ — Advances in Pathophysiology and Therapeutic Paradigm Shifts in Chronic Spontaneous Urticaria: A Narr
- T4 PMC11177578 ↗ — EHA2024 Hybrid Congress
- T6 41009465 ↗ — Role of Mast Cells in Human Health and Disease: Controversies and Novel Therapies
- T6 41044830 ↗ — An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment
- T6 41654334 ↗ — Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
- T6 41270830 ↗ — Emerging IgE and non-IgE targeted therapies for chronic urticaria
T4 — Case series
MCAS
14 sources
- T6 16931578 ↗ — JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper
- T6 26419263 ↗ — Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis
- T6 19802503 ↗ — Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology
- T6 36350500 ↗ — Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylas
- T6 29455764 ↗ — Management protocols for chronic heart failure in India
- T6INDIRECT 22191008 ↗ — Acquired pincer nail deformity associated with renal failure
- T6INDIRECT 40597783 ↗ — A case of chronic myelomonocytic related lysozyme-induced nephropathy
- T6INDIRECT 35445052 ↗ — Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxa
- T6INDIRECT 31248788 ↗ — Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terap
- T4 PMC7463038 ↗ — Abstracts TPS
- T4 PMC13254489 ↗ — Publication Only
- T4 PMC9429973 ↗ — Abstract Book for the 27th Congress of the European Hematology Association
- T6 26604845 ↗ — The contributions of the European Medicines Agency and its pediatric committee to the fight against
- T6 35620165 ↗ — Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis
Decitabine/Cedazuridine
T4
T4 — Case series
MCAS
16 sources
- T6 35008250 ↗ — FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review
- T6 33670524 ↗ — Therapeutic Advances in Oncology
- T6 38163206 ↗ — FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and
- T6 36140335 ↗ — The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target
- T6 35236051 ↗ — How I diagnose and treat chronic myelomonocytic leukemia
- T6INDIRECT 39649724 ↗ — KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique
- T6INDIRECT 40597783 ↗ — A case of chronic myelomonocytic related lysozyme-induced nephropathy
- T6INDIRECT 41378161 ↗ — Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options
- T6INDIRECT 37576366 ↗ — Managing Drug Interactions With Oral Anticancer Treatments
- T6INDIRECT 41947786 ↗ — Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine
- T4 PMC12163242 ↗ — Publication Only
- T4 PMC12163243 ↗ — Plenary Abstracts Session & Oral Presentations
- T4 PMC11177578 ↗ — EHA2024 Hybrid Congress
- T6 33792103 ↗ — Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia
- T6 41514619 ↗ — Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia?
- T6 35663104 ↗ — Chronic Myelomonocytic Leukemia: Hematopathology Perspective
T4 — Case series
MCAS
19 sources
- T6 NCT00237627 ↗ — Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic C
- T6 31275462 ↗ — PEGylated liposomes: immunological responses
- T6 33857566 ↗ — Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
- T6 33571463 ↗ — Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines
- T6 15785749 ↗ — NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour a
- T6 35941223 ↗ — Cancer nanomedicine
- T6INDIRECT 34107163 ↗ — Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The r
- T6INDIRECT 39640056 ↗ — Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosin
- T6INDIRECT 41155644 ↗ — Immunomodulatory Activities of Emerging Rare Ginsenosides F1, Rg5, Rk1, Rh1, and Rg2: From Molecular
- T6INDIRECT 38182056 ↗ — Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in P
- T6INDIRECT 30561866 ↗ — "Abstracts of the 77th Annual Meeting of the Japanese Cancer Association; 2018 Sept 27-29; Osaka, Ja
- T4 PMC9421640 ↗ — 21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 Septem
- T4 PMC8901205 ↗ — Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020
- T4 PMC7161412 ↗ — Hematopoietic Tumors
- T6 26265306 ↗ — Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
- T6 36768330 ↗ — Nanomaterials and Their Impact on the Immune System
- T6 26246897 ↗ — Clinical development methodology for infusion-related reactions with monoclonal antibodies
- T6 37054953 ↗ — Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
- T6 37009262 ↗ — Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy
T4 — Case series
MCAS
15 sources
- T6 NCT04681105 ↗ — Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malig
- T6INDIRECT 33129938 ↗ — Live long and active: Polypeptide-mediated assembly of antibody variable fragments
- T6 34039409 ↗ — The landscape of bispecific T cell engager in cancer treatment
- T6 31547472 ↗ — CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
- T6 30280288 ↗ — Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
- T6 34572809 ↗ — Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications
- T6 35368047 ↗ — Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice gui
- T6INDIRECT 34071099 ↗ — BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?
- T6INDIRECT 34833353 ↗ — Precision Medicine in Systemic Mastocytosis
- T6INDIRECT 32692611 ↗ — Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia
- T4 PMC12163242 ↗ — Publication Only
- T4 PMC11177578 ↗ — EHA2024 Hybrid Congress
- T6 33113953 ↗ — CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies
- T6 38904305 ↗ — Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
- T6 34581774 ↗ — The promise and perils of immunotherapy
T4 — Case series
MCAS
12 sources
- T6 36145292 ↗ — Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
- T6 33291602 ↗ — Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
- T6 39415291 ↗ — Natural killer cell-based cancer immunotherapy: from basics to clinical trials
- T6 40550903 ↗ — Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and comb
- T6 40483473 ↗ — Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic
- T4 PMC3563175 ↗ — XII Congress of the Italian Society of Experimental Hematology
- T6INDIRECT 1356450 ↗ — Annual congress of the Austrian Society of Hematology and Oncology and the Hungarian Societies of He
- T4 PMC13254489 ↗ — Publication Only
- T4 PMC7161786 ↗ — Abstracts of papers presented at the Second Meeting of the European Haematology Association, Paris,
- T4 PMC7103153 ↗ — Satellite Symposia and Meet-the-Professor Sessions : Satellite Symposium I
- T6 39513028 ↗ — Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46
- T6 39310179 ↗ — Identification of Potential Tryptase Inhibitors from FDA-Approved Drugs Using Machine Learning, Mole
T4 — Case series
MCAS
13 sources
- T6 15867089 ↗ — Blocking IL-1 in systemic inflammation
- T6 31900383 ↗ — Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
- T6 38177104 ↗ — The role of inflammasomes in human diseases and their potential as therapeutic targets
- T6 21143856 ↗ — The Schnitzler syndrome
- T6 31850638 ↗ — Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics
- T6INDIRECT 40615199 ↗ — Expanding the Patient Pool for Rilonacept
- T6INDIRECT 37602078 ↗ — Adult-Onset Still's Disease (AOSD) Associated With Collagenous Colitis (CC) and Basedow's Disease: A
- T6INDIRECT 21659854 ↗ — Biologic modulators in allergic and autoinflammatory diseases
- T6INDIRECT 24085684 ↗ — Abstracts of the 2013 Annual Meeting of the American College of Rheumatology. October 25-30, 2013. S
- T4 PMC11103445 ↗ — Abstracts of the ECTS 2024 Congress
- T6 33534121 ↗ — Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
- T6 41085563 ↗ — The NLRP3 inflammasome: a pivotal orchestrator of multisystem diseases-from molecular mechanisms to
- T6 35658515 ↗ — Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recur
T4 — Case series
MCAS
18 sources
- T6INDIRECT 36096203 ↗ — Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneo
- T6 36183125 ↗ — BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms
- T6 31446134 ↗ — New treatments for chronic urticaria
- T6 38101757 ↗ — Feast for thought: A comprehensive review of food allergy 2021-2023
- T6 35175630 ↗ — Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatologic
- T6INDIRECT 38492772 ↗ — Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
- T6INDIRECT 40532792 ↗ — Current and future landscape of Bruton tyrosine kinase inhibitors in allergy
- T6INDIRECT 39598410 ↗ — Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
- T6INDIRECT 35956071 ↗ — Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease
- T6INDIRECT 40845419 ↗ — Chronic spontaneous urticaria: update on pathogenesis and therapeutic implications
- T6INDIRECT 42194774 ↗ — A Neuroendocrine-Immune Model of Hidradenitis Suppurativa: Mechanistic Insights into Pain, Pruritus,
- T6INDIRECT 38621708 ↗ — British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease
- T4 PMC10913204 ↗ — 2023 CSACI annual scientific meeting book of abstracts
- T6 32401033 ↗ — A Fast and Clean BTK Inhibitor
- T6 34778053 ↗ — Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Ma
- T6 31743962 ↗ — Critical Points on the Use of Biologicals in Allergic Diseases and Asthma
- T6 33880321 ↗ — The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders
- T6 34141049 ↗ — The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria,
T4 — Case series
MCAS
10 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6 25452424 ↗ — Immunology and skin in health and disease
- T6 15090422 ↗ — Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent o
- T6INDIRECT 20596252 ↗ — T-cell infiltration in autosomal dominant neovascular inflammatory vitreoretinopathy
- T6 21437065 ↗ — Update on the management of chronic eczema: new approaches and emerging treatment options
- T6 24085684 ↗ — Abstracts of the 2013 Annual Meeting of the American College of Rheumatology. October 25-30, 2013. S
- T6INDIRECT 24737224 ↗ — Abstracts from the 37th Annual Meeting of the Society of General Internal Medicine, 2014, San Diego,
- T6INDIRECT 32394034 ↗ — 2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference
- T6INDIRECT 28188499 ↗ — 2017 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference
- T4 PMC7168573 ↗ — The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Pos
Non sedating H1-antihistamine
T4
T4 — Case series
MCAS
17 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 28818095 ↗ — Frequency, distribution and immunologic nature of infusion reactions in subjects receiving peglotica
- T6 30924425 ↗ — Chronic Urticaria: An Overview of Treatment and Recent Patents
- T6 24817895 ↗ — Leukotriene receptor antagonists for chronic urticaria: a systematic review
- T6 26120520 ↗ — Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects
- T6 PMC6494532 ↗ — Interventions for chronic idiopathic urticaria excluding antihistamines
- T6 24034140 ↗ — Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria
- T6 25705232 ↗ — Insights and advances in chronic urticaria: a Canadian perspective
- T6 31906999 ↗ — Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spo
- T6INDIRECT 25694628 ↗ — The association of cholinergic and cold-induced urticaria: diagnosis and management
- T6INDIRECT 34513518 ↗ — A Woman With Solar Urticaria and Heat Urticaria: A Unique Presentation of an Individual With Multipl
- T6INDIRECT 34457015 ↗ — Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment
- T4 PMC7129269 ↗ — ABSTRACT BOOK
- T6 35683540 ↗ — Drugs and Vaccines Hypersensitivity in Children with Mastocytosis
- T6 28210286 ↗ — Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions
- T6 28698528 ↗ — Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments
- T6 33643777 ↗ — Expert consensus on practical aspects in the treatment of chronic urticaria
Psychosocial Assessment And Care
T4
T4 — Case series
MCAS
7 sources
T4 — Case series
MCASPOTS
30 sources
- T6 NCT00449748 ↗ — Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
- T6INDIRECT 24407160 ↗ — Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6 21235428 ↗ — Mechanisms of drug resistance in kinases
- T6 26654227 ↗ — Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell l
- T6 27549339 ↗ — Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
- T6 18559612 ↗ — Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases,
- T6 20038218 ↗ — Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients wi
- T6 24323045 ↗ — Autophagy and human diseases
- T6 31277291 ↗ — A Comprehensive Review of Autophagy and Its Various Roles in Infectious, Non-Infectious, and Lifesty
- T6 20814256 ↗ — Emerging pharmacotherapies for neurodevelopmental disorders
- T6 34944054 ↗ — Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease
- T6 22695254 ↗ — Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane
- T6INDIRECT 20405294 ↗ — Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus
- T6INDIRECT 23258954 ↗ — Clinical application of development of nonantibiotic macrolides that correct inflammation-driven imm
- T6INDIRECT 26062813 ↗ — Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloprol
- T6INDIRECT 27507155 ↗ — IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells
- T6INDIRECT 19259308 ↗ — Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors
- T6INDIRECT 21484580 ↗ — The 21st conference of the asian pacific association for the study of the liver : oral presentations
- T6INDIRECT 30561866 ↗ — "Abstracts of the 77th Annual Meeting of the Japanese Cancer Association; 2018 Sept 27-29; Osaka, Ja
- T4 PMC7163973 ↗ — Poster Presentations
- T6 17934482 ↗ — Aberrant cytokine signaling in leukemia
- T6 32435640 ↗ — Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improve
- T6 21372221 ↗ — Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a
- T6INDIRECT 34559267 ↗ — European Association of Nuclear Medicine October 20-23, 2021 Virtual
- T6INDIRECT 30480124 ↗ — Program Abstracts from the 21st International Association of Gerontology and Geriatrics (IAGG) World
- T6INDIRECT 28894880 ↗ — EANM'17
- T4 PMC6216117 ↗ — Abstracts from the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncolog
- T4 PMC4894295 ↗ — 21st Congress of the European Hematology Association Copenhagen, Denmark, June 9–12, 2016
- T4 PMC2888565 ↗ — 15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010
T4 — Case series
MCAS
14 sources
- T6 34824210 ↗ — The JAK/STAT signaling pathway: from bench to clinic
- T6 35755063 ↗ — Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- T6 37188939 ↗ — Protein kinases: drug targets for immunological disorders
- T6 39014279 ↗ — Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
- T6 40260013 ↗ — Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- T6INDIRECT 41737950 ↗ — Alopecia Areata - Effects of Treatment with Upadacitinib - Two Case Reports
- T6INDIRECT 37510908 ↗ — Beard Alopecia: An Updated and Comprehensive Review of Etiologies, Presentation and Treatment
- T6INDIRECT 36860609 ↗ — JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal
- T4 PMC13299356 ↗ — Deucravacitinib in dermatology: current indication and existing off-label data
- T6INDIRECT 42196158 ↗ — Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-S
- T6INDIRECT 41969750 ↗ — Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- T6 39513029 ↗ — Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions
- T6 37212867 ↗ — New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- T6 41654334 ↗ — Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
T4 — Case series
MCAS
10 sources
- T6 NCT01481909 ↗ — Study on Mastocytosis for Rupatadine Treatment
- T6INDIRECT 33911601 ↗ — Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Pa
- T6INDIRECT 34583772 ↗ — Long term treatment with omalizumab in adolescent with refractory solar urticaria
- T6 23120659 ↗ — Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis
- T6 34212158 ↗ — Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART)
- T6 PMC7424594 ↗ — Abstracts of the XXII World Allergy Congress, 4-8 December, 2011 Cancún, México
- T4 PMC3513125 ↗ — 275 Efficacy of Omalizumab in the Treatment of Urticaria-Vasculitis Associated to Churg-Strauss Synd
- T6 PMC9441222 ↗ — Abstracts, 17. Deutscher Allergiekongress, Wiesbaden, 8.-10. September 2022
- T6 PMC9382619 ↗ — Abstracts of the 17th German Allergy Congress, Wiesbaden, 08.–10. September 2022
- T6 PMC9524336 ↗ — Abstracts der 30. Jahrestagung der Deutschen Gesellschaft für Schlafforschung und Schlafmedizin e. V
T4 — Case series
MCAS
14 sources
- T6 19860730 ↗ — Update on Hsp90 inhibitors in clinical trial
- T6 30687710 ↗ — Epidermolysis Bullosa Acquisita: The 2019 Update
- T6 14551138 ↗ — 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutiv
- T6 22714264 ↗ — The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestina
- T6 37100345 ↗ — The exoprotein Gbp of Fusobacterium nucleatum promotes THP-1 cell lipid deposition by binding to Cyp
- T6INDIRECT 22577569 ↗ — Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directio
- T4 PMC8901205 ↗ — Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020
- T4 PMC3684198 ↗ — 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013
- T4 PMC2707164 ↗ — 14th Congress of the European Hematology Association, Berlin, Germany, June 4–7, 2009
- T6 31357735 ↗ — Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
- T6 40768641 ↗ — Tissue Fibrosis Decoded via Cellular Senescence: Mechanisms, Treatments, and Emerging Technologies
- T6 40987035 ↗ — PDGFRA in paediatric high-grade glioma - target or distraction?
- T6 36313712 ↗ — Inflammatory microenvironment in classical Hodgkin's lymphoma with special stress on mast cells
- T6 34495872 ↗ — HSP90 acts as a senomorphic target in senescent retinal pigmental epithelial cells
non sedating H1-antihistamine
T4
T4 — Case series
MCAS
17 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 28818095 ↗ — Frequency, distribution and immunologic nature of infusion reactions in subjects receiving peglotica
- T6 30924425 ↗ — Chronic Urticaria: An Overview of Treatment and Recent Patents
- T6 24817895 ↗ — Leukotriene receptor antagonists for chronic urticaria: a systematic review
- T6 26120520 ↗ — Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects
- T6 PMC6494532 ↗ — Interventions for chronic idiopathic urticaria excluding antihistamines
- T6 24034140 ↗ — Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria
- T6 25705232 ↗ — Insights and advances in chronic urticaria: a Canadian perspective
- T6 31906999 ↗ — Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spo
- T6INDIRECT 25694628 ↗ — The association of cholinergic and cold-induced urticaria: diagnosis and management
- T6INDIRECT 34513518 ↗ — A Woman With Solar Urticaria and Heat Urticaria: A Unique Presentation of an Individual With Multipl
- T6INDIRECT 34457015 ↗ — Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment
- T4 PMC7129269 ↗ — ABSTRACT BOOK
- T6 35683540 ↗ — Drugs and Vaccines Hypersensitivity in Children with Mastocytosis
- T6 28210286 ↗ — Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions
- T6 28698528 ↗ — Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments
- T6 33643777 ↗ — Expert consensus on practical aspects in the treatment of chronic urticaria
T5 — Case report
MCAS
17 sources
- T6 27536065 ↗ — Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
- T6 23639648 ↗ — Gastrointestinal stromal tumors
- T6 19011754 ↗ — Therapeutic protein kinase inhibitors
- T6 36849435 ↗ — Molecular and functional imaging in cancer-targeted therapy: current applications and future directi
- T6 27363818 ↗ — Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FD
- T6 39666929 ↗ — Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI
- T6INDIRECT 35619994 ↗ — Presumed bilateral diffuse uveal melanocytic proliferation - A case report and review of literature
- T5 20737043 ↗ — Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 27843641 ↗ — ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
- T6INDIRECT 36145679 ↗ — Ocular Drug Delivery: Advancements and Innovations
- T6INDIRECT 36607590 ↗ — TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors
- T6INDIRECT 39640056 ↗ — Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosin
- T6INDIRECT 41790711 ↗ — Unveiling the risk: A comprehensive analysis of drug-induced aphthous ulcers using real-world data f
- T6 21125679 ↗ — The GIST paradigm: lessons for other kinase-driven cancers
- T6 24636470 ↗ — Food allergy: Insights into etiology, prevention, and treatment provided by murine models
- T6 33198314 ↗ — Tyrosine Kinase Receptors in Oncology
T6 — Mechanistic / preclinical
MCAS
7 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 37024900 ↗ — The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a
- T6 35562767 ↗ — Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydr
- T6 24167521 ↗ — TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients
- T6 25829981 ↗ — Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria
- T6INDIRECT 41277234 ↗ — Gut microbiota dysbiosis at the interface of neuropsychiatric disorders and their dermatological com
- T6 42305426 ↗ — Intranasal Corticosteroids Versus Second-Generation Antihistamines for Allergic Rhinitis in Adolesce
T6 — Mechanistic / preclinical
MCAS
12 sources
- T6INDIRECT 25397904 ↗ — H1-antihistamines for chronic spontaneous urticaria
- T6INDIRECT 37024900 ↗ — The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a
- T6INDIRECT 20226302 ↗ — The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficu
- T6 31416456 ↗ — Management of chronic urticaria in children: a clinical guideline
- T6 25878559 ↗ — Bilastine: new insight into antihistamine treatment
- T6 28035215 ↗ — The role and choice criteria of antihistamines in allergy management - expert opinion
- T6INDIRECT 25155177 ↗ — Abstracts from the European Academy of Allergy and Clinical Immunology Congress, 7-11 June, 2014, Co
- T6 34000363 ↗ — Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hype
- T6 23667312 ↗ — Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
- T6 25829981 ↗ — Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria
- T6 27293247 ↗ — Updosing of Nonsedating Anti-histamines in Recalcitrant Chronic Urticaria
- T6 30745975 ↗ — The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the
T6 — Mechanistic / preclinical
MCAS
25 sources
- T6INDIRECT 31749986 ↗ — Efficacy and safety of topical and systemic medications: a systematic literature review informing th
- T6INDIRECT 34504395 ↗ — The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A System
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 35316551 ↗ — A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendat
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 38139057 ↗ — The Effects of Periodontal Treatment on Rheumatoid Arthritis and of Anti-Rheumatic Drugs on Periodon
- T6INDIRECT 22875601 ↗ — Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficac
- T6INDIRECT 24559487 ↗ — Effect of intermittent aerobic exercise on sleep quality and sleep disturbances in patients with rhe
- T6INDIRECT 22162990 ↗ — Psychophysiological responses to stress after stress management training in patients with rheumatoid
- T6INDIRECT 31484730 ↗ — Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Dif
- T6INDIRECT 28242845 ↗ — Focal Segmental Glomerulosclerosis
- T6INDIRECT 32571129 ↗ — Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients
- T6INDIRECT 26347200 ↗ — Relationship between Periodontitis and Rheumatoid Arthritis: Review of the Literature
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 34739716 ↗ — COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History
- T6INDIRECT 27242652 ↗ — Idiopathic Inflammatory Myopathies: Clinical Approach and Management
- T6INDIRECT 32327425 ↗ — EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events
- T6INDIRECT 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 30774631 ↗ — The Immunology of Macrophage Activation Syndrome
- T6 38762484 ↗ — Regulatory mechanisms of PD-1/PD-L1 in cancers
- T6 37198232 ↗ — Targeting strategies for bone diseases: signaling pathways and clinical studies
- T6 35755063 ↗ — Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- T6 37849038 ↗ — Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
- T6 25433021 ↗ — Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardio
- T6 26509054 ↗ — EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
T6 — Mechanistic / preclinical
MCAS
26 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6 NCT04681105 ↗ — Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malig
- T6INDIRECT 30968949 ↗ — Home use of interdental cleaning devices, in addition to toothbrushing, for preventing and controlli
- T6INDIRECT 28514613 ↗ — KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
- T6INDIRECT 15947280 ↗ — Inflammatory basis of exercise-induced bronchoconstriction
- T6INDIRECT 37459086 ↗ — Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penic
- T6INDIRECT 26282650 ↗ — Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD
- T6INDIRECT 7798537 ↗ — Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive as
- T6INDIRECT 26342029 ↗ — Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast
- T6 28293453 ↗ — An overview and management of osteoporosis
- T6 25287861 ↗ — Calcitonin gene-related peptide: physiology and pathophysiology
- T6 27188216 ↗ — Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics
- T6INDIRECT 33821570 ↗ — Delivery of oligonucleotide-based therapeutics: challenges and opportunities
- T6INDIRECT 27351598 ↗ — Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders
- T6INDIRECT 26690128 ↗ — Mast Cell-Mediated Mechanisms of Nociception
- T6INDIRECT 27242652 ↗ — Idiopathic Inflammatory Myopathies: Clinical Approach and Management
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6INDIRECT 21224201 ↗ — American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the d
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6INDIRECT 24859366 ↗ — Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid d
- T6 31275462 ↗ — PEGylated liposomes: immunological responses
- T6 29467654 ↗ — The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
- T6 26233910 ↗ — Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer
- T6 19815110 ↗ — Mechanisms of mast cell signaling in anaphylaxis
- T6 25182228 ↗ — Clinician's Guide to Prevention and Treatment of Osteoporosis
- T6 35478046 ↗ — The clinician's guide to prevention and treatment of osteoporosis
T6 — Mechanistic / preclinical
MCAS
21 sources
- T6INDIRECT 27091121 ↗ — Fingolimod for relapsing-remitting multiple sclerosis
- T6INDIRECT 38822024 ↗ — Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and met
- T6INDIRECT 32990324 ↗ — Anti-cytokine targeted therapies for ANCA-associated vasculitis
- T6INDIRECT 37487610 ↗ — The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected h
- T6INDIRECT 37486733 ↗ — The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected H
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 38473835 ↗ — The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systema
- T6INDIRECT 26109102 ↗ — Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
- T6INDIRECT 23935024 ↗ — Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after red
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 32107531 ↗ — Pediatric hemophagocytic lymphohistiocytosis
- T6INDIRECT 29915719 ↗ — Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy
- T6INDIRECT 31547472 ↗ — CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 27242652 ↗ — Idiopathic Inflammatory Myopathies: Clinical Approach and Management
- T6INDIRECT 22285672 ↗ — Pruritus in cutaneous T-cell lymphoma: a review
- T6 19231593 ↗ — Biology of the eosinophil
- T6 20538328 ↗ — Practical approach to the patient with hypereosinophilia
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
- T6 26654227 ↗ — Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell l
Allogeneic Bone Marrow Transplantation
T6
T6 — Mechanistic / preclinical
MCAS
18 sources
- T6INDIRECT 23660070 ↗ — Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders
- T6 27834397 ↗ — The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
- T6 25062998 ↗ — Mast cell function: a new vision of an old cell
- T6 18507503 ↗ — Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a s
- T6 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 18559612 ↗ — Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases,
- T6INDIRECT 35976468 ↗ — SOCS1 Haploinsufficiency Presenting as Severe Enthesitis, Bone Marrow Hypocellularity, and Refractor
- T6INDIRECT 19590986 ↗ — Evidence for the use of intravenous immunoglobulins--a review of the literature
- T6INDIRECT 22224765 ↗ — Monogenic autoimmunity
- T6INDIRECT 25284845 ↗ — Biologics in dermatology: an integrated review
- T6INDIRECT 14692959 ↗ — Universal leukoreduction and acute transfusion reactions: putting the puzzle together
- T6INDIRECT 21837236 ↗ — Eosinophilic colitis: university of Minnesota experience and literature review
- T6INDIRECT 37122022 ↗ — French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic
- T6 7949167 ↗ — Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic
- T6 37188939 ↗ — Protein kinases: drug targets for immunological disorders
- T6 29232931 ↗ — Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis
- T6 32107539 ↗ — Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder
- T6 26088795 ↗ — Osteonecrosis of the femoral head: diagnosis and classification systems
Anti-Thymocyte Globulin
T6
T6 — Mechanistic / preclinical
MCAS
22 sources
- T6INDIRECT 34402927 ↗ — Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myoc
- T6INDIRECT 32990324 ↗ — Anti-cytokine targeted therapies for ANCA-associated vasculitis
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 41273190 ↗ — Systematic Review of Immune and Symptomatic Treatments for Stiff-Person Syndrome
- T6INDIRECT 41622196 ↗ — Clinical characteristics and treatment outcomes in thymoma- related aplastic anemia: a case report a
- T6INDIRECT 20978268 ↗ — First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases
- T6INDIRECT 21047561 ↗ — Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term
- T6INDIRECT 30077015 ↗ — Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignan
- T6 35732831 ↗ — The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid
- T6 32107531 ↗ — Pediatric hemophagocytic lymphohistiocytosis
- T6INDIRECT 33657207 ↗ — How I manage acquired pure red cell aplasia in adults
- T6INDIRECT 31475005 ↗ — Recurrent and <i>de novo</i> Glomerulonephritis After Kidney Transplantation
- T6INDIRECT 32421085 ↗ — Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in
- T6INDIRECT 34031556 ↗ — Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidel
- T6INDIRECT 33880680 ↗ — Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Find
- T6INDIRECT 24790407 ↗ — Ocular manifestations of idiopathic aplastic anemia: retrospective study and literature review
- T6 33936095 ↗ — Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
- T6 25352848 ↗ — T cells in vascular inflammatory diseases
- T6 38361991 ↗ — Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical
- T6 29868474 ↗ — Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions
- T6 20353479 ↗ — Recent progress and new perspectives in studying T cell responses to allografts
- T6 27011916 ↗ — Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantati
Anti-thymoglobulin, rabbit
T6
T6 — Mechanistic / preclinical
MCAS
2 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6 26999538 ↗ — Physicians Poster SessionsPoster Session / Day 1
Assessment Of Therapy Complications
T6
T6 — Mechanistic / preclinical
MCAS
Autologous mesenchymal stem cell
T6
T6 — Mechanistic / preclinical
MCAS
6 sources
- T6 34200905 ↗ — Cell-Based Therapies for Traumatic Brain Injury: Therapeutic Treatments and Clinical Trials
- T6 34468946 ↗ — Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
- T6 25476233 ↗ — Bone marrow stromal cells as immunomodulators. A primer for dermatologists
- T6 29740250 ↗ — Ilizarov method in combination with autologous mesenchymal stem cells from iliac crest shows improve
- T6 33957957 ↗ — Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropath
- T6INDIRECT 42149419 ↗ — Diseases of the tongue: a review of etiologies and treatments
T6 — Mechanistic / preclinical
RegisteredWithdrawnMCAS
22 sources
- T6WITHDRAWN NCT01773395 ↗ — GVAX vs. Placebo for MDS/AML After Allo HSCT
- T6 NCT01384513 ↗ — A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Mali
- T6REGISTERED-ONLY NCT03779854 ↗ — Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults
- T6INDIRECT 33823925 ↗ — Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstruct
- T6INDIRECT 41622196 ↗ — Clinical characteristics and treatment outcomes in thymoma- related aplastic anemia: a case report a
- T6INDIRECT 31495201 ↗ — GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous t
- T6 23060872 ↗ — Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodefici
- T6 23508552 ↗ — A proposed role for neutrophil extracellular traps in cancer immunoediting
- T6 27845343 ↗ — Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate imm
- T6 25154823 ↗ — Hematopoietic stem-cell transplantation for advanced systemic mastocytosis
- T6 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 33513372 ↗ — MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 31723789 ↗ — Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the Euro
- T6INDIRECT 33875812 ↗ — Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approac
- T6INDIRECT 30858685 ↗ — Primary vitreoretinal lymphoma: prevalence, impact, and management challenges
- T6INDIRECT 28261062 ↗ — Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Defic
- T6INDIRECT 20137004 ↗ — Emesis in dogs: a review
- T6INDIRECT 29503529 ↗ — Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
- T6 24618482 ↗ — Etiopathogenesis of cataract: an appraisal
- T6 22830345 ↗ — Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor
- T6 24598853 ↗ — Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible
T6 — Mechanistic / preclinical
MCAS
18 sources
- T6INDIRECT 40415544 ↗ — Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria
- T6 34063789 ↗ — Mast Cells: A New Frontier for Cancer Immunotherapy
- T6 35469840 ↗ — KIT as a master regulator of the mast cell lineage
- T6 33685605 ↗ — Biologics for the Use in Chronic Spontaneous Urticaria: When and Which
- T6 35304158 ↗ — Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local pr
- T6 35184297 ↗ — Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a health
- T6INDIRECT 37717255 ↗ — Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments
- T6INDIRECT 37190096 ↗ — Mast Cells as a Target-A Comprehensive Review of Recent Therapeutic Approaches
- T6INDIRECT 38791201 ↗ — Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
- T6INDIRECT 39028396 ↗ — New insights into chronic inducible urticaria
- T6INDIRECT 33615122 ↗ — Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy?
- T6INDIRECT 39598410 ↗ — Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
- T6INDIRECT 36776192 ↗ — Biologicals in Treatment of Chronic Urticaria: A Narrative Review
- T6INDIRECT 35956071 ↗ — Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease
- T6 39158477 ↗ — Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways
- T6 38630620 ↗ — Mast cells: a novel therapeutic avenue for cardiovascular diseases?
- T6 36430941 ↗ — Human Lung Mast Cells: Therapeutic Implications in Asthma
- T6 38289515 ↗ — Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabiliz
T6 — Mechanistic / preclinical
MCAS
3 sources
- T6 40004611 ↗ — Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Pe
- T6 41654334 ↗ — Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
- T6 41270830 ↗ — Emerging IgE and non-IgE targeted therapies for chronic urticaria
T6 — Mechanistic / preclinical
MCAS
23 sources
- T6 NCT00979160 ↗ — Evaluation of Response of Dasatinib to Treat Mastocytosis
- T6 NCT00255346 ↗ — Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
- T6INDIRECT 38474862 ↗ — Quercetin in the Prevention of Induced Periodontal Disease in Animal Models: A Systematic Review and
- T6INDIRECT 33952306 ↗ — Anticancer drugs repurposed for Alzheimer's disease: a systematic review
- T6INDIRECT 24407160 ↗ — Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic
- T6INDIRECT 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T6INDIRECT 31207054 ↗ — Development and evaluation of a computable phenotype to identify pediatric patients with leukemia an
- T6 22834835 ↗ — Functions of S100 proteins
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6 18684881 ↗ — Mast cells and mastocytosis
- T6 23656643 ↗ — Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6INDIRECT 34039409 ↗ — The landscape of bispecific T cell engager in cancer treatment
- T6INDIRECT 35343828 ↗ — Salivary gland function, development, and regeneration
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6 24359404 ↗ — Targeting the PDGF signaling pathway in tumor treatment
- T6 22043171 ↗ — A clinical overview of centrosome amplification in human cancers
- T6 16721371 ↗ — AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
- T6 24963404 ↗ — Imatinib: a breakthrough of targeted therapy in cancer
T6 — Mechanistic / preclinical
MCAS
21 sources
- T6INDIRECT 34176557 ↗ — Epigenetics of obstructive sleep apnea syndrome: a systematic review
- T6INDIRECT 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T6INDIRECT 21047561 ↗ — Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term
- T6INDIRECT 24498169 ↗ — Promoter DNA methylation of farnesoid X receptor and pregnane X receptor modulates the intrahepatic
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 27036965 ↗ — Role of TET enzymes in DNA methylation, development, and cancer
- T6 31676858 ↗ — TIM3 comes of age as an inhibitory receptor
- T6 27834397 ↗ — The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
- T6 38762484 ↗ — Regulatory mechanisms of PD-1/PD-L1 in cancers
- T6 24859366 ↗ — Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid d
- T6INDIRECT 32962122 ↗ — Atypical Chronic Myeloid Leukemia: Where Are We Now?
- T6INDIRECT 34774343 ↗ — A review of FLT3 inhibitors in acute myeloid leukemia
- T6INDIRECT 31547472 ↗ — CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
- T6INDIRECT 31723789 ↗ — Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the Euro
- T6INDIRECT 34071099 ↗ — BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?
- T6INDIRECT 34893494 ↗ — Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
- T6INDIRECT 35494081 ↗ — Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosi
- T6INDIRECT 29966370 ↗ — The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation
- T6 26679767 ↗ — Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive
- T6 25693834 ↗ — DNMT3A in haematological malignancies
- T6 24136165 ↗ — The genetic basis of myelodysplasia and its clinical relevance
Donor Lymphocyte Infusion
T6
T6 — Mechanistic / preclinical
MCAS
14 sources
- T6 NCT01384513 ↗ — A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Mali
- T6 23023713 ↗ — Pathogenesis of follicular lymphoma
- T6 34039409 ↗ — The landscape of bispecific T cell engager in cancer treatment
- T6 21083034 ↗ — Relapse after allogeneic stem cell transplantation
- T6 24859366 ↗ — Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid d
- T6 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6INDIRECT 29025582 ↗ — A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia
- T6INDIRECT 23483057 ↗ — A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast
- T6INDIRECT 33466873 ↗ — Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective
- T6INDIRECT 36599826 ↗ — Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
- T6INDIRECT 14692959 ↗ — Universal leukoreduction and acute transfusion reactions: putting the puzzle together
- T6 34572809 ↗ — Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications
- T6 22125447 ↗ — Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside
- T6 31616632 ↗ — Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Rece
T6 — Mechanistic / preclinical
MCAS
16 sources
- T6 29619379 ↗ — Eosinophils from Physiology to Disease: A Comprehensive Review
- T6 31547472 ↗ — CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
- T6 31244579 ↗ — Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease
- T6INDIRECT 20934998 ↗ — Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatin
- T6 18721759 ↗ — Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrog
- T6INDIRECT 35874756 ↗ — Roles of Mast Cells in Cutaneous Diseases
- T6INDIRECT 35629101 ↗ — Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Mu
- T6INDIRECT 18545251 ↗ — Indications and results of cord blood transplant in children with leukemia
- T6INDIRECT 33311612 ↗ — The 46<sup>th</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Phy
- T6INDIRECT 30161072 ↗ — Recommendations on Selection and Processing of RBC Components for Pediatric Patients From the Pediat
- T6INDIRECT 29603868 ↗ — American Society of Pediatric Hematology/Oncology (ASPHO), David L. Lawrence Convention Center, Pitt
- T6 38223477 ↗ — CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
- T6 36969182 ↗ — Impact of oral microbiota on pathophysiology of GVHD
- T6 20525151 ↗ — Progress and challenges in the understanding of chronic urticaria
- T6 34815400 ↗ — Long-term repair of porcine articular cartilage using cryopreservable, clinically compatible human e
- T6 32907809 ↗ — IgE-Mediated Immune Response and Antibody-Mediated Rejection
Donor Natural Killer Cell Infusion
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
19 sources
- T6INDIRECT 17684963 ↗ — [Erythropoetin and iron preparations in the treatment of anemia in patients with chronic kidney dise
- T6 16931578 ↗ — JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper
- T6 19802503 ↗ — Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology
- T6 18559612 ↗ — Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases,
- T6 29217782 ↗ — Rational management approach to pure red cell aplasia
- T6 32807237 ↗ — Repurposed agents in the Alzheimer's disease drug development pipeline
- T6INDIRECT 36350500 ↗ — Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylas
- T6INDIRECT 30830058 ↗ — Drug desensitization in allergic children
- T6INDIRECT 25278804 ↗ — Peripheral ulcerative keratitis: Our challenging experience
- T6INDIRECT 35445052 ↗ — Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxa
- T6INDIRECT 27114361 ↗ — Abstracts from the 2016 Society of General Internal Medicine Annual Meeting
- T6INDIRECT 34808742 ↗ — Angiotensin-Converting Enzyme Inhibitor-Induced Non-allergic Perioral Angioedema: A Case-Based Scopi
- T6INDIRECT 31333273 ↗ — Abstracts Presented at the 120th Annual Meeting of the American Association of Colleges of Pharmacy,
- T6INDIRECT 33410314 ↗ — XVI Congress of the Italian Society of Experimental Hematology, Napoli, Italy, October 15-17, 2020
- T6 27551882 ↗ — Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise
- T6 27382321 ↗ — Biosimilars: potential implications for clinicians
- T6 38731114 ↗ — A Review of Key Regulators of Steady-State and Ineffective Erythropoiesis
- T6 28452907 ↗ — In a Mouse Model of Sepsis, Hepcidin Ablation Ameliorates Anemia More Effectively than Iron and Eryt
- T6 28370957 ↗ — Safety of intravenous iron in hemodialysis patients
Fatigue Assessment And Management
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
21 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6INDIRECT 17943799 ↗ — Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma
- T6INDIRECT 34388994 ↗ — What is the impact of granulocyte colony-stimulating factor (G-CSF) in subcutaneous injection or int
- T6INDIRECT 38682756 ↗ — Autologous platelet-rich plasma for assisted reproduction
- T6INDIRECT 41273190 ↗ — Systematic Review of Immune and Symptomatic Treatments for Stiff-Person Syndrome
- T6INDIRECT 41408611 ↗ — Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemot
- T6 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6 27340273 ↗ — Inflammatory Disequilibrium in Stroke
- T6 34774343 ↗ — A review of FLT3 inhibitors in acute myeloid leukemia
- T6 18378569 ↗ — Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with
- T6 20008633 ↗ — Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoprolifera
- T6INDIRECT 33611854 ↗ — Burkitt lymphoma and lactic acidosis: A case report and review of the literature
- T6INDIRECT 31473638 ↗ — Macrophage activation syndrome/haemophagocytic lymphohistiocytosis secondary to <i>Burkholderia cepa
- T6INDIRECT 31461919 ↗ — Antibiotic Hypersensitivity Mechanisms
- T6INDIRECT 33443626 ↗ — Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy fo
- T6INDIRECT 28397154 ↗ — Abstracts from the 2017 Society of General Internal Medicine Annual Meeting
- T6 29051803 ↗ — Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and sys
- T6 30135011 ↗ — Drug Hypersensitivity
- T6 28993751 ↗ — Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials
- T6 32375354 ↗ — Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
- T6 36061305 ↗ — Lactic Acid Regulation: A Potential Therapeutic Option in Rheumatoid Arthritis
T6 — Mechanistic / preclinical
MCAS
2 sources
- T6INDIRECT 25563312 ↗ — Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex kera
- T6INDIRECT 37954648 ↗ — Cerebral venous thrombosis caused by spontaneous intracranial hypotension due to spontaneous spinal
T6 — Mechanistic / preclinical
MCAS
Graft Versus Host Disease Prophylaxis/Therapy
T6
T6 — Mechanistic / preclinical
MCAS
H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
1 source
- T6 35729334 ↗ — IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting
T6 — Mechanistic / preclinical
MCAS
Human interleukin-2 injection
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
1 source
- T6 33628747 ↗ — Anti-IgE for the Treatment of Chronic Urticaria
Infection Prophylaxis And Management
T6
T6 — Mechanistic / preclinical
MCAS
2 sources
- T6 41000203 ↗ — Tocilizumab for Non-Infectious Uveitis: A Systematic Review
- T6 41694401 ↗ — Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response r
T6 — Mechanistic / preclinical
MCAS
18 sources
- T6INDIRECT 32990324 ↗ — Anti-cytokine targeted therapies for ANCA-associated vasculitis
- T6INDIRECT 29141858 ↗ — Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recen
- T6 31900383 ↗ — Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
- T6 20583979 ↗ — Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong d
- T6 31850638 ↗ — Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics
- T6 PMC6464318 ↗ — Anti‐cytokine targeted therapies for ANCA‐associated vasculitis
- T6 19234101 ↗ — IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolys
- T6INDIRECT 25784780 ↗ — Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, peril
- T6INDIRECT 25284976 ↗ — Pharmacotherapy for uveitis: current management and emerging therapy
- T6INDIRECT 23970817 ↗ — Biological treatments: new weapons in the management of monogenic autoinflammatory disorders
- T6INDIRECT 32421085 ↗ — Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in
- T6INDIRECT 36422739 ↗ — Pathogenesis and current therapies for non-infectious uveitis
- T6INDIRECT 32823391 ↗ — Interleukins and cytokine biomarkers in uveitis
- T6INDIRECT 28203051 ↗ — A review and update on orphan drugs for the treatment of noninfectious uveitis
- T6INDIRECT 32508634 ↗ — New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
- T6 27308503 ↗ — Mechanisms underlying skin disorders induced by EGFR inhibitors
- T6 32973505 ↗ — Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
- T6 37123122 ↗ — <i>Porphyromonas Gingivalis</i> in the Development of Periodontitis: Impact on Dysbiosis and Inflamm
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
24 sources
- T6INDIRECT 39817495 ↗ — The Association Between Serum Gamma-Glutamyl Transferase and Gastrointestinal Cancer Risk: A Systema
- T6INDIRECT 33832066 ↗ — The necessity or not of the addition of fusion to decompression for lumbar degenerative spondylolist
- T6INDIRECT 36424485 ↗ — Effectiveness of using platelet-rich fibrin to increase keratinized tissue around the tooth in the m
- T6INDIRECT 41364023 ↗ — High-frequency repetitive transcranial magnetic stimulation for stroke patients lower extremity func
- T6INDIRECT 34408396 ↗ — Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular D
- T6 32973505 ↗ — Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
- T6 34693230 ↗ — Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR,
- T6 25190696 ↗ — Non-Hodgkin's lymphomas, version 4.2014
- T6 26022641 ↗ — Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With D
- T6 27104962 ↗ — Macular Thickness Measurements with Frequency Domain-OCT for Quantification of Retinal Neural Loss a
- T6INDIRECT 34297318 ↗ — Abstracts from the 2021 Annual Meeting of the Society of General Internal Medicine
- T6INDIRECT 30240102 ↗ — Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP) Kyoto, J
- T6INDIRECT 26041557 ↗ — Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25
- T6INDIRECT 3979758 ↗ — Abstracts of papers submitted to the American Gastroenterological Association. 86th annual meeting,
- T6INDIRECT 24085684 ↗ — Abstracts of the 2013 Annual Meeting of the American College of Rheumatology. October 25-30, 2013. S
- T6INDIRECT 28397154 ↗ — Abstracts from the 2017 Society of General Internal Medicine Annual Meeting
- T6INDIRECT 24737224 ↗ — Abstracts from the 37th Annual Meeting of the Society of General Internal Medicine, 2014, San Diego,
- T6INDIRECT 31090026 ↗ — Abstracts from the 2019 Annual Meeting of the Society of General Internal Medicine
- T6 40720603 ↗ — Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis
- T6 40074986 ↗ — Update on the Treatment of Chronic Spontaneous Urticaria
- T6 28163052 ↗ — Airway and serum biochemical correlates of refractory neutrophilic asthma
- T6 24663285 ↗ — Impact of cigarette smoke on the human and mouse lungs: a gene-expression comparison study
- T6 40773543 ↗ — Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens
- T6 29290940 ↗ — Lysophosphatidylcholine induces cytotoxicity/apoptosis and IL-8 production of human endothelial cell
T6 — Mechanistic / preclinical
MCAS
7 sources
- T6 29528507 ↗ — Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review
- T6 39956859 ↗ — Molecular principles underlying aggressive cancers
- T6 38239190 ↗ — Current trends and future prospects of drug repositioning in gastrointestinal oncology
- T6 33643693 ↗ — Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular intersti
- T6 39213447 ↗ — Nodular regenerative hyperplasia: The role of the CK7 immunohistochemistry pattern of expression in
- T6INDIRECT 34692291 ↗ — Methotrexate-Induced Septicemia With Severe Pancytopenia and Diffuse Cutaneous Ulcerative Lesions
- T6 PMC7119909 ↗ — Pharmacology and Pharmacotherapy
Management Of Therapy Complications
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
23 sources
- T6INDIRECT 40052535 ↗ — Models of care for managing non-specific low back pain
- T6INDIRECT 26037730 ↗ — Acupuncture for the sequelae of Bell's palsy: a randomized controlled trial
- T6INDIRECT 37684652 ↗ — Evaluation of the efficacy of manual soft tissue therapy and therapeutic exercises in patients with
- T6INDIRECT 32819949 ↗ — Comparing two dry needling interventions for plantar heel pain: a randomised controlled trial
- T6INDIRECT 25537784 ↗ — Acupuncture at Houxi (SI 3) acupoint for acute neck pain caused by stiff neck: study protocol for a
- T6INDIRECT 30679283 ↗ — Is a government-regulated rehabilitation guideline more effective than general practitioner educatio
- T6INDIRECT 21388554 ↗ — Acupuncture for sequelae of Bell's palsy: a randomized controlled trial protocol
- T6INDIRECT 35546396 ↗ — Assessment of the masseter stiffness in patients during conservative therapy for masticatory muscle
- T6 33711512 ↗ — Pain in sickle cell disease: current and potential translational therapies
- T6 35478046 ↗ — The clinician's guide to prevention and treatment of osteoporosis
- T6INDIRECT 20405294 ↗ — Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus
- T6INDIRECT 28963668 ↗ — Assessing and treating primary headaches and cranio-facial pain in patients undergoing rehabilitatio
- T6INDIRECT 19714234 ↗ — Chiropractic practice in military and veterans health care: The state of the literature
- T6INDIRECT 30203232 ↗ — Topical Selenium Sulfide for the Treatment of Hyperkeratosis
- T6INDIRECT 36008648 ↗ — World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2022)
- T6INDIRECT 33429811 ↗ — Tuina for lumbar disc herniation: A protocol for systematic review and meta analysis
- T6 38067127 ↗ — Complementary Approaches to Retinal Health Focusing on Diabetic Retinopathy
- T6 38878809 ↗ — Unmet Need: Mechanistic and Translational Studies of Sickle Cell Disease Pain as a Whole-Person Heal
- T6 31508307 ↗ — Quantitative ultrasound imaging monitoring progressive disuse osteopenia and mechanical stimulation
- T6 25414775 ↗ — The Leaves of Broussonetia kazinoki Siebold Inhibit Atopic Dermatitis-Like Response on Mite Allergen
- T6 27114361 ↗ — Abstracts from the 2016 Society of General Internal Medicine Annual Meeting
- T6 21255460 ↗ — Effectiveness of trigger point dry needling for plantar heel pain: study protocol for a randomised c
- T6 25671182 ↗ — Antimicrobial and Antifungal Activity of Pelargonium roseum Essential Oils
Methotrexate + anti-H1
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
23 sources
- T6 NCT00109707 ↗ — A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malign
- T6INDIRECT 29614103 ↗ — Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study
- T6INDIRECT 33952306 ↗ — Anticancer drugs repurposed for Alzheimer's disease: a systematic review
- T6INDIRECT 24407160 ↗ — Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic
- T6INDIRECT 35640224 ↗ — Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosi
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 28031180 ↗ — Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
- T6 24359404 ↗ — Targeting the PDGF signaling pathway in tumor treatment
- T6 22043171 ↗ — A clinical overview of centrosome amplification in human cancers
- T6 30713991 ↗ — The growing role of precision and personalized medicine for cancer treatment
- T6 18559612 ↗ — Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases,
- T6INDIRECT 25964669 ↗ — How I treat hypereosinophilic syndromes
- T6INDIRECT 29431216 ↗ — Mast cell-neural interactions contribute to pain and itch
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 27132234 ↗ — Pharmacological treatment options for mast cell activation disease
- T6INDIRECT 19491913 ↗ — Tyrosine kinases as targets for the treatment of rheumatoid arthritis
- T6INDIRECT 28725969 ↗ — Mastocytosis: from a Molecular Point of View
- T6 16721371 ↗ — AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
- T6 24963404 ↗ — Imatinib: a breakthrough of targeted therapy in cancer
- T6 37143582 ↗ — Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, an
- T6 29925402 ↗ — Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
19 sources
- T6INDIRECT 32990324 ↗ — Anti-cytokine targeted therapies for ANCA-associated vasculitis
- T6 29682504 ↗ — Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
- T6 29035619 ↗ — Personalized medicine with biologics for severe type 2 asthma: current status and future prospects
- T6 32004747 ↗ — Current and Future Treatments of Rhinitis and Sinusitis
- T6 39158477 ↗ — Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways
- T6 PMC6464318 ↗ — Anti‐cytokine targeted therapies for ANCA‐associated vasculitis
- T6 28121072 ↗ — Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development
- T6INDIRECT 32421085 ↗ — Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in
- T6INDIRECT 35987486 ↗ — Safety of Biologics for Atopic Diseases During Pregnancy
- T6INDIRECT 37259416 ↗ — Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future
- T6INDIRECT 27803792 ↗ — Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential
- T6INDIRECT 33891135 ↗ — Lessons learned from targeting eosinophils in human disease
- T6INDIRECT 32915172 ↗ — Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic
- T6 28716883 ↗ — Role of the β Common (βc) Family of Cytokines in Health and Disease
- T6 35628333 ↗ — Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets
- T6 26620589 ↗ — Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17
- T6 39062104 ↗ — Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases
- T6 35296105 ↗ — A pragmatic guide to choosing biologic therapies in severe asthma
- T6 32378146 ↗ — Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches
T6 — Mechanistic / preclinical
MCAS
7 sources
- T6 NCT02478957 ↗ — Treatment of Indolent Systemic Mastocytosis With PA101
- T6INDIRECT 33085095 ↗ — Curbing the Cough: Multimodal Treatments for Neurogenic Cough: A Systematic Review and Meta-Analysis
- T6 36836843 ↗ — Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
- T6 27942432 ↗ — Mast Cell Clonal Disorders: Classification, Diagnosis and Management
- T6 37006099 ↗ — Approach to post COVID-19 persistent cough: A narrative review
- T6 32944204 ↗ — Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer
- T6 40904938 ↗ — Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Manageme
T6 — Mechanistic / preclinical
MCAS
21 sources
- T6 NCT00237627 ↗ — Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic C
- T6INDIRECT 37314034 ↗ — Pharmacological interventions for pruritus in adult palliative care patients
- T6INDIRECT 36580956 ↗ — Risk of perioperative stroke and cerebral autoregulation monitoring: a systematic review
- T6INDIRECT 37572360 ↗ — Interventions for bullous pemphigoid
- T6INDIRECT 36613529 ↗ — Reported Cases and Diagnostics of Occupational Insect Allergy: A Systematic Review
- T6INDIRECT 34351016 ↗ — Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19
- T6 32632432 ↗ — Half a century of amyloids: past, present and future
- T6 10456976 ↗ — Cytokines in asthma
- T6 28782570 ↗ — Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healin
- T6 24679069 ↗ — Sublingual immunotherapy: World Allergy Organization position paper 2013 update
- T6 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 12194881 ↗ — Hazardous air pollutants and asthma
- T6INDIRECT 19590986 ↗ — Evidence for the use of intravenous immunoglobulins--a review of the literature
- T6INDIRECT 37295474 ↗ — Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evalu
- T6INDIRECT 25416152 ↗ — HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current
- T6INDIRECT 14692959 ↗ — Universal leukoreduction and acute transfusion reactions: putting the puzzle together
- T6INDIRECT 21886384 ↗ — ELECTROPHYSICAL AGENTS - Contraindications And Precautions: An Evidence-Based Approach To Clinical D
- T6 11842096 ↗ — Natural and pharmacological regulation of telomerase
- T6 22154653 ↗ — Role of reactive oxygen and nitrogen species in the vascular responses to inflammation
- T6 11405550 ↗ — Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma
- T6 21939239 ↗ — Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lyso
T6 — Mechanistic / preclinical
MCAS
22 sources
- T6 NCT00424242 ↗ — Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
- T6INDIRECT 34999267 ↗ — Metastases in the Pineal Region: A Systematic Review of Clinical Features, Management Strategies, an
- T6INDIRECT 32546683 ↗ — A comprehensive map of disease networks and molecular drug discoveries for glaucoma
- T6INDIRECT 23760662 ↗ — Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metast
- T6INDIRECT 33331923 ↗ — Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a mul
- T6INDIRECT 27737534 ↗ — ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplati
- T6INDIRECT 24777247 ↗ — T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
- T6INDIRECT 33123580 ↗ — Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases
- T6 26391154 ↗ — Targeted therapy in cancer
- T6 36254250 ↗ — Small molecule inhibitors targeting the cancers
- T6 38462638 ↗ — Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
- T6INDIRECT 30307375 ↗ — Diagnosis of NUT carcinoma of lung origin by next-generation sequencing: case report and review of t
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 31909151 ↗ — Cutaneous lupus erythematosus: A review of the literature
- T6INDIRECT 30832285 ↗ — PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Liter
- T6INDIRECT 34295668 ↗ — International consensus on severe lung cancer-the first edition
- T6INDIRECT 29535794 ↗ — Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments
- T6INDIRECT 36835299 ↗ — Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions
- T6 34834162 ↗ — Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
- T6 36947256 ↗ — Receptor tyrosine kinase inhibitors in cancer
- T6 32775973 ↗ — When should we order a next generation sequencing test in a patient with cancer?
- T6 25079860 ↗ — Acute interstitial nephritis - a reappraisal and update
Peripheral Blood Stem Cell Transplantation
T6
T6 — Mechanistic / preclinical
MCAS
22 sources
- T6INDIRECT 21047561 ↗ — Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term
- T6INDIRECT 30635050 ↗ — Predictors of responders to mononuclear stem cell-based therapeutic angiogenesis for no-option criti
- T6INDIRECT 30077015 ↗ — Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignan
- T6 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6 25221694 ↗ — Xerostomia due to systemic disease: a review of 20 conditions and mechanisms
- T6 30858685 ↗ — Primary vitreoretinal lymphoma: prevalence, impact, and management challenges
- T6 21079133 ↗ — Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acut
- T6 19822304 ↗ — Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell
- T6 23799412 ↗ — A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patient
- T6 29517616 ↗ — A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Aut
- T6INDIRECT 28761296 ↗ — Primary Cutaneous Nocardiosis Caused by <i>Nocardia takedensis</i>
- T6INDIRECT 25143680 ↗ — Intravascular cytotoxic T-cell lymphoma in a young immunocompetent woman
- T6INDIRECT 25550705 ↗ — Wernicke's encephalopathy in a child with high dose thiamine therapy
- T6INDIRECT 31592543 ↗ — 17th International Congress of Immunology, 19-23 October 2019, Beijing, China
- T6INDIRECT 30240102 ↗ — Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP) Kyoto, J
- T6INDIRECT 18545251 ↗ — Indications and results of cord blood transplant in children with leukemia
- T6 36655373 ↗ — Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities
- T6 26604845 ↗ — The contributions of the European Medicines Agency and its pediatric committee to the fight against
- T6 31311585 ↗ — Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related os
- T6 36831022 ↗ — Primary Mediastinal Germ Cell Tumors: A Thorough Literature Review
- T6 34357128 ↗ — Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Ger
- T6 38249974 ↗ — Neutrophilic and eosinophilic dermatoses associated with hematological malignancy
Peripheral blood stem cell transplantation
T6
T6 — Mechanistic / preclinical
MCAS
22 sources
- T6INDIRECT 21047561 ↗ — Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term
- T6INDIRECT 30635050 ↗ — Predictors of responders to mononuclear stem cell-based therapeutic angiogenesis for no-option criti
- T6INDIRECT 30077015 ↗ — Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignan
- T6 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6 25221694 ↗ — Xerostomia due to systemic disease: a review of 20 conditions and mechanisms
- T6 30858685 ↗ — Primary vitreoretinal lymphoma: prevalence, impact, and management challenges
- T6 21079133 ↗ — Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acut
- T6 19822304 ↗ — Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell
- T6 23799412 ↗ — A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patient
- T6 29517616 ↗ — A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Aut
- T6INDIRECT 28761296 ↗ — Primary Cutaneous Nocardiosis Caused by <i>Nocardia takedensis</i>
- T6INDIRECT 25143680 ↗ — Intravascular cytotoxic T-cell lymphoma in a young immunocompetent woman
- T6INDIRECT 25550705 ↗ — Wernicke's encephalopathy in a child with high dose thiamine therapy
- T6INDIRECT 31592543 ↗ — 17th International Congress of Immunology, 19-23 October 2019, Beijing, China
- T6INDIRECT 30240102 ↗ — Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP) Kyoto, J
- T6INDIRECT 18545251 ↗ — Indications and results of cord blood transplant in children with leukemia
- T6 36655373 ↗ — Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities
- T6 26604845 ↗ — The contributions of the European Medicines Agency and its pediatric committee to the fight against
- T6 31311585 ↗ — Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related os
- T6 36831022 ↗ — Primary Mediastinal Germ Cell Tumors: A Thorough Literature Review
- T6 34357128 ↗ — Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Ger
- T6 38249974 ↗ — Neutrophilic and eosinophilic dermatoses associated with hematological malignancy
Probio Histamed®, a multi-species probiotic preparation containing Bifid. breve, Bifid. lactis, Bifid. infantis, Bifid. longum, Lact. gasseri, and Lact. rhamnosus
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
20 sources
- T6INDIRECT 32990324 ↗ — Anti-cytokine targeted therapies for ANCA-associated vasculitis
- T6INDIRECT 33129321 ↗ — Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis
- T6INDIRECT 35359659 ↗ — Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinica
- T6INDIRECT 35350578 ↗ — Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis
- T6INDIRECT 33129938 ↗ — Live long and active: Polypeptide-mediated assembly of antibody variable fragments
- T6 26121197 ↗ — Inflammasomes: mechanism of action, role in disease, and therapeutics
- T6 25625584 ↗ — NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflamm
- T6 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6 30670444 ↗ — The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
- T6 31900383 ↗ — Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 25905009 ↗ — Schnitzler's syndrome: lessons from 281 cases
- T6INDIRECT 25784780 ↗ — Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, peril
- T6INDIRECT 22120610 ↗ — Interplay between innate and adaptive immunity in the development of non-infectious uveitis
- T6INDIRECT 23970817 ↗ — Biological treatments: new weapons in the management of monogenic autoinflammatory disorders
- T6INDIRECT 30021447 ↗ — Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
- T6 38177104 ↗ — The role of inflammasomes in human diseases and their potential as therapeutic targets
- T6 26209330 ↗ — Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
- T6 36031601 ↗ — Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
- T6 35729334 ↗ — IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting
T6 — Mechanistic / preclinical
MCAS
20 sources
- T6INDIRECT 34019122 ↗ — Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomiz
- T6INDIRECT 32990324 ↗ — Anti-cytokine targeted therapies for ANCA-associated vasculitis
- T6INDIRECT 35359659 ↗ — Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinica
- T6INDIRECT 41424786 ↗ — Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and
- T6INDIRECT 37612352 ↗ — A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19
- T6 34824210 ↗ — The JAK/STAT signaling pathway: from bench to clinic
- T6 37332039 ↗ — T cells in health and disease
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 32467561 ↗ — Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered
- T6 34253862 ↗ — Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
- T6INDIRECT 33867315 ↗ — The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 29521875 ↗ — Cytokines in uveitis
- T6INDIRECT 32963819 ↗ — Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the
- T6INDIRECT 33073244 ↗ — Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?
- T6INDIRECT 33040064 ↗ — COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- T6INDIRECT 33485845 ↗ — Systemic diseases and the cornea
- T6 37198232 ↗ — Targeting strategies for bone diseases: signaling pathways and clinical studies
- T6 36031601 ↗ — Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
T6 — Mechanistic / preclinical
MCAS
1 source
- T6 36948491 ↗ — Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical C
Sodium Ferric Gluconate Complex In Sucrose
T6
T6 — Mechanistic / preclinical
MCAS
3 sources
- T6 31855154 ↗ — Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic dise
- T6 PMC7123236 ↗ — Hematology
- T6 PMC7120116 ↗ — Hematology
T6 — Mechanistic / preclinical
MCAS
16 sources
- T6 NCT00186628 ↗ — Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- T6INDIRECT 34402927 ↗ — Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myoc
- T6INDIRECT 37598195 ↗ — Sialendoscopy approach in treating juvenile recurrent parotitis: a systematic review
- T6 36485140 ↗ — Approach to the patient with suspected hypereosinophilic syndrome
- T6 28721077 ↗ — Food protein-induced enterocolitis syndrome - a review of the literature with focus on clinical mana
- T6 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 38565581 ↗ — Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for mu
- T6INDIRECT 32834714 ↗ — Inflammatory Manifestations of Systemic Diseases in the Central Nervous System
- T6INDIRECT 14692959 ↗ — Universal leukoreduction and acute transfusion reactions: putting the puzzle together
- T6INDIRECT 25621178 ↗ — Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility wit
- T6INDIRECT 34297318 ↗ — Abstracts from the 2021 Annual Meeting of the Society of General Internal Medicine
- T6INDIRECT 28397154 ↗ — Abstracts from the 2017 Society of General Internal Medicine Annual Meeting
- T6 3979758 ↗ — Abstracts of papers submitted to the American Gastroenterological Association. 86th annual meeting,
- T6 32725471 ↗ — Abstracts from the 2020 Annual Meeting of the Society of General Internal Medicine
- T6 32546955 ↗ — Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Reversal of Edematous Punctal Occlusio
- T6 34357128 ↗ — Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Ger
Standard Follow-Up Care
T6
T6 — Mechanistic / preclinical
MCAS
Stem cell transplantation
T6
T6 — Mechanistic / preclinical
MCAS
21 sources
- T6INDIRECT 28644114 ↗ — Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- T6INDIRECT 34904799 ↗ — Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
- T6INDIRECT 36542826 ↗ — Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the p
- T6INDIRECT 31113476 ↗ — Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenc
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T6INDIRECT 34649563 ↗ — COVID-19 infection in adult patients with hematological malignancies: a European Hematology Associat
- T6 35732831 ↗ — The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid
- T6 32934330 ↗ — Exploring the NK cell platform for cancer immunotherapy
- T6 35767897 ↗ — International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphol
- T6 32855385 ↗ — Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clin
- T6INDIRECT 33219338 ↗ — Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease
- T6INDIRECT 23023713 ↗ — Pathogenesis of follicular lymphoma
- T6INDIRECT 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6INDIRECT 20113479 ↗ — Rothmund-Thomson syndrome
- T6INDIRECT 23109216 ↗ — Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for p
- T6 20176269 ↗ — IgE, mast cells, basophils, and eosinophils
- T6 38311623 ↗ — Extracellular vesicles as tools and targets in therapy for diseases
- T6 25861976 ↗ — Ion channels in innate and adaptive immunity
- T6 27834397 ↗ — The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
- T6 28484466 ↗ — The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
- T6 33657296 ↗ — Diffuse Large B-Cell Lymphoma
T6 — Mechanistic / preclinical
MCAS
2 sources
- T6 41654334 ↗ — Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
- T6 41270830 ↗ — Emerging IgE and non-IgE targeted therapies for chronic urticaria
T6 — Mechanistic / preclinical
Harm signalMCAS
1 source
- T6HARM NCT00457288 ↗ — Efficacy and Safety of TF002 in Cutaneous Mastocytosis
T6 — Mechanistic / preclinical
MCAS
1 source
- T6 39376275 ↗ — Comparison of the Efficacy and Safety of Bilastine 20 mg versus Fexofenadine 180 mg for Treatment of
Tab Bilastine + Tab Levocetrizine
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
23 sources
- T6INDIRECT 31782132 ↗ — Pathophysiology and Therapeutic Perspectives of Oxidative Stress and Neurodegenerative Diseases: A N
- T6INDIRECT 26680308 ↗ — Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?
- T6INDIRECT 37189381 ↗ — Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- T6INDIRECT 30184451 ↗ — Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- T6INDIRECT 30943337 ↗ — Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome
- T6INDIRECT 28069279 ↗ — Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placeb
- T6INDIRECT 22733017 ↗ — Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
- T6INDIRECT 38659046 ↗ — Long-term remission and survival in patients with relapsed or refractory multiple myeloma after trea
- T6 37169756 ↗ — Angiogenic signaling pathways and anti-angiogenic therapy for cancer
- T6 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 32106302 ↗ — Overview of Castleman disease
- T6INDIRECT 20643990 ↗ — Narrative review: the systemic capillary leak syndrome
- T6INDIRECT 35606650 ↗ — Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treat
- T6INDIRECT 29222231 ↗ — AL amyloidosis: from molecular mechanisms to targeted therapies
- T6INDIRECT 23109216 ↗ — Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for p
- T6INDIRECT 25154823 ↗ — Hematopoietic stem-cell transplantation for advanced systemic mastocytosis
- T6 27834397 ↗ — The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
- T6 26679767 ↗ — Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive
- T6 30042333 ↗ — Interleukin-1 Beta-A Friend or Foe in Malignancies?
- T6 22043171 ↗ — A clinical overview of centrosome amplification in human cancers
- T6 37143582 ↗ — Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, an
- T6 19366917 ↗ — Update on eosinophilic meningoencephalitis and its clinical relevance
- T6 14760748 ↗ — Key role of mast cells and their major secretory products in inflammatory bowel disease
T6 — Mechanistic / preclinical
MCAS
17 sources
- T6 24876674 ↗ — The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis
- T6 33077936 ↗ — Kinase inhibition in autoimmunity and inflammation
- T6 35504917 ↗ — COVID-19 vaccine development: milestones, lessons and prospects
- T6 37143582 ↗ — Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, an
- T6 28346442 ↗ — Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
- T6INDIRECT 33628747 ↗ — Anti-IgE for the Treatment of Chronic Urticaria
- T6INDIRECT 37386330 ↗ — Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
- T6INDIRECT 40004611 ↗ — Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Pe
- T6INDIRECT 39598410 ↗ — Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
- T6INDIRECT 37193304 ↗ — Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2
- T6INDIRECT 31592543 ↗ — 17th International Congress of Immunology, 19-23 October 2019, Beijing, China
- T6INDIRECT 30240102 ↗ — Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP) Kyoto, J
- T6 36814257 ↗ — Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS)
- T6 38405060 ↗ — Cholesterol metabolism: physiological regulation and diseases
- T6 36251242 ↗ — New Mechanistic Advances in FcεRI-Mast Cell-Mediated Allergic Signaling
- T6 33923680 ↗ — Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
- T6 35008250 ↗ — FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review
T6 — Mechanistic / preclinical
MCAS
17 sources
- T6INDIRECT 27428352 ↗ — Corticosteroids for Bell's palsy (idiopathic facial paralysis)
- T6INDIRECT 31117264 ↗ — Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data
- T6INDIRECT 25254615 ↗ — Interventions for the management of oral ulcers in Behçet's disease
- T6 36639608 ↗ — Long COVID: major findings, mechanisms and recommendations
- T6 32106302 ↗ — Overview of Castleman disease
- T6 35215786 ↗ — <i>Herpes zoster</i>: A Review of Clinical Manifestations and Management
- T6 36213536 ↗ — Carbohydrate-based drugs launched during 2000<i>-</i>2021
- T6 15870014 ↗ — In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
- T6 36690406 ↗ — Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral th
- T6INDIRECT 32778962 ↗ — Repurposing of Kinase Inhibitors for Treatment of COVID-19
- T6INDIRECT 32522746 ↗ — Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- T6INDIRECT 30619688 ↗ — Common viral infections in kidney transplant recipients
- T6INDIRECT 30859513 ↗ — A Review of Corneal Endotheliitis and Endotheliopathy: Differential Diagnosis, Evaluation, and Treat
- T6 31031754 ↗ — Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syn
- T6 27597852 ↗ — Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematolog
- T6 36831439 ↗ — Oral Human Papillomavirus Benign Lesions and HPV-Related Cancer in Healthy Children: A Systematic Re
- T6 34840688 ↗ — Intravitreal Methotrexate
T6 — Mechanistic / preclinical
MCAS
21 sources
- T6 NCT00237627 ↗ — Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic C
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 29699936 ↗ — IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets
- T6 26654227 ↗ — Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell l
- T6 19490893 ↗ — A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
- T6 20404331 ↗ — Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits
- T6 21447728 ↗ — Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patient
- T6 28103725 ↗ — A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lym
- T6 20540156 ↗ — Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinic
- T6INDIRECT 31040892 ↗ — Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case re
- T6INDIRECT 37724175 ↗ — Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and lite
- T6INDIRECT 33911709 ↗ — Necrobiotic Xanthogranuloma Coexists with Diffuse Normolipidemic Plane Xanthoma and Multiple Myeloma
- T6INDIRECT 31183267 ↗ — Thrombocytosis as an Initial Presentation of Plasma Cell Neoplasm: A Case Report
- T6INDIRECT 34456724 ↗ — The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products i
- T6INDIRECT 18545251 ↗ — Indications and results of cord blood transplant in children with leukemia
- T6INDIRECT 33311612 ↗ — The 46<sup>th</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Phy
- T6INDIRECT 32745248 ↗ — Abstracts from the European Academy of Allergy and Clinical Immunology Congress, 26-30 May 2018, Mun
- T6 19616124 ↗ — Nanodelivery in airway diseases: challenges and therapeutic applications
- T6 28862319 ↗ — Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps,
- T6 33923680 ↗ — Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
- T6 23209294 ↗ — Proteasome-dependent activation of mammalian target of rapamycin complex 1 (mTORC1) is essential for
T6 — Mechanistic / preclinical
MCAS
1 source
- T6INDIRECT 28330497 ↗ — Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczem
Xolair Prefilled Syringe
T6
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCAS
19 sources
- T6INDIRECT 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6INDIRECT 28435464 ↗ — Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of F
- T6INDIRECT 28330497 ↗ — Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczem
- T6INDIRECT 24176117 ↗ — A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic pa
- T6INDIRECT 17765756 ↗ — Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
- T6INDIRECT 29737044 ↗ — A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens
- T6 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6 24642143 ↗ — Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes aller
- T6INDIRECT 23341807 ↗ — Treatment of severe cold contact urticaria with omalizumab: case reports
- T6INDIRECT 25754717 ↗ — Biologic therapies targeting eosinophils: current status and future prospects
- T6INDIRECT 28725969 ↗ — Mastocytosis: from a Molecular Point of View
- T6INDIRECT 32421085 ↗ — Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in
- T6INDIRECT 33628747 ↗ — Anti-IgE for the Treatment of Chronic Urticaria
- T6INDIRECT 37259416 ↗ — Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future
- T6INDIRECT 32915172 ↗ — Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic
- T6 29035619 ↗ — Personalized medicine with biologics for severe type 2 asthma: current status and future prospects
- T6 34212542 ↗ — COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI U
- T6 32086776 ↗ — The Role of Mast Cells in IgE-Independent Lung Diseases
- T6 29163536 ↗ — Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desen
T6 — Mechanistic / preclinical
MCAS
T6 — Mechanistic / preclinical
MCASPOTS
51 sources
- T6 NCT00006251 ↗ — Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by C
- T6 NCT00014235 ↗ — Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transpla
- T6 NCT00118352 ↗ — Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophen
- T6 NCT00112593 ↗ — Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and M
- T6INDIRECT 21497847 ↗ — AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome
- T6INDIRECT 37056675 ↗ — The crucial role and mechanism of insulin resistance in metabolic disease
- T6INDIRECT 30968949 ↗ — Home use of interdental cleaning devices, in addition to toothbrushing, for preventing and controlli
- T6INDIRECT 26110030 ↗ — Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid:
a systematic review
- T6INDIRECT 10951147 ↗ — Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria
- T6INDIRECT 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T6INDIRECT 20431041 ↗ — Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and l
- T6INDIRECT 29652551 ↗ — n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease
- T6INDIRECT 30943337 ↗ — Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome
- T6 22878108 ↗ — Cell biology of ischemia/reperfusion injury
- T6INDIRECT 32114706 ↗ — Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- T6INDIRECT 24554461 ↗ — Echinacea for preventing and treating the common cold
- T6INDIRECT 25919144 ↗ — Interventions for rosacea
- T6INDIRECT 29271481 ↗ — Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
- T6INDIRECT 35603936 ↗ — Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
- T6INDIRECT 31917873 ↗ — Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
- T6INDIRECT 22251436 ↗ — Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of pati
- T6 28293453 ↗ — An overview and management of osteoporosis
- T6 33243615 ↗ — Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on
- T6 37436070 ↗ — Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
- T6INDIRECT 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 25686388 ↗ — The pathophysiology, diagnosis, and treatment of dry eye disease
- T6INDIRECT 24275598 ↗ — Treating inflammation by blocking interleukin-1 in humans
- T6INDIRECT 28242845 ↗ — Focal Segmental Glomerulosclerosis
- T6INDIRECT 30558872 ↗ — Antibiotic allergy
- T6INDIRECT 32106302 ↗ — Overview of Castleman disease
- T6 26228647 ↗ — Colchicine--Update on mechanisms of action and therapeutic uses
- T6 25861976 ↗ — Ion channels in innate and adaptive immunity
- T6 28736339 ↗ — TFOS DEWS II pain and sensation report
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 30774631 ↗ — The Immunology of Macrophage Activation Syndrome
- T6INDIRECT 31485575 ↗ — Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
- T6INDIRECT 29399043 ↗ — Treatment strategies for autoimmune encephalitis
- T6INDIRECT 23184849 ↗ — Grapefruit-medication interactions: forbidden fruit or avoidable consequences?
- T6INDIRECT 29442540 ↗ — Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor The
- T6INDIRECT 23147521 ↗ — Clinical guideline: management of gastroparesis
- T6INDIRECT 31210940 ↗ — European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gl
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6 29565029 ↗ — Hypertension
- T6 34988090 ↗ — Treatment of Inflammatory Bowel Disease: A Comprehensive Review
- T6 19165601 ↗ — Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps
- T6 23241069 ↗ — A review of the efficacy and safety of oral antidiabetic drugs
- T6 33909761 ↗ — Brazilian Guidelines of Hypertension - 2020
- T6 25182228 ↗ — Clinician's Guide to Prevention and Treatment of Osteoporosis
- T6 35478046 ↗ — The clinician's guide to prevention and treatment of osteoporosis
- T6 30354828 ↗ — Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the Ameri
- T6 31080465 ↗ — 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Commit
diphenhydramine (H1 antihistamine)
T6
T6 — Mechanistic / preclinical
MCASPOTS
43 sources
- T6INDIRECT 25046337 ↗ — Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who rema
- T6INDIRECT 29650949 ↗ — Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
- T6INDIRECT 20226302 ↗ — The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficu
- T6INDIRECT 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6INDIRECT 12867500 ↗ — Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin
- T6INDIRECT 10377184 ↗ — Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-indu
- T6INDIRECT 24176117 ↗ — A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic pa
- T6INDIRECT 33786700 ↗ — Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infect
- T6INDIRECT 18774392 ↗ — Treatment of chronic autoimmune urticaria with omalizumab
- T6 36639608 ↗ — Long COVID: major findings, mechanisms and recommendations
- T6INDIRECT 30175841 ↗ — Interventions to improve the appropriate use of polypharmacy for older people
- T6INDIRECT 29744873 ↗ — Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - as
- T6INDIRECT 23633371 ↗ — Interventions for treating pain and disability in adults with complex regional pain syndrome
- T6INDIRECT 22376048 ↗ — American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in o
- T6INDIRECT 18787227 ↗ — Antipsychotic therapy during early and late pregnancy. A systematic review
- T6INDIRECT 28893208 ↗ — Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients
- T6 37160297 ↗ — Antidepressants for pain management in adults with chronic pain: a network meta-analysis
- T6 29442540 ↗ — Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor The
- T6INDIRECT 15577865 ↗ — Rhinosinusitis: establishing definitions for clinical research and patient care
- T6INDIRECT 15577816 ↗ — Rhinosinusitis: Establishing definitions for clinical research and patient care
- T6INDIRECT 32436290 ↗ — EAACI Allergen Immunotherapy User's Guide
- T6INDIRECT 24813302 ↗ — Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of a
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6 27795547 ↗ — Food allergy: immune mechanisms, diagnosis and immunotherapy
- T6 26869768 ↗ — Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chit
- T6 37230968 ↗ — Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome
- T6 33204386 ↗ — World allergy organization anaphylaxis guidance 2020
- T6 21460831 ↗ — TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch
- T6 21134576 ↗ — Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAI
- T6INDIRECT 22021174 ↗ — The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor sy
- T6INDIRECT 26084539 ↗ — International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
- T6INDIRECT 19484833 ↗ — Evidence-based recommendations for the assessment and management of sleep disorders in older persons
- T6INDIRECT 37139824 ↗ — American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medicatio
- T6INDIRECT 23147521 ↗ — Clinical guideline: management of gastroparesis
- T6 21034217 ↗ — Orexin receptors: pharmacology and therapeutic opportunities
- T6 30018614 ↗ — Immune System Dysregulation During Spaceflight: Potential Countermeasures for Deep Space Exploration
- T6 34589395 ↗ — Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic n
- T6 29055040 ↗ — THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
- T6 26650439 ↗ — The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
- T6 29852897 ↗ — Insomnia in the Elderly: A Review
- T6 10457047 ↗ — Childhood functional gastrointestinal disorders
- T6 31080465 ↗ — 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Commit
epinephrine (adrenaline)
T6
T6 — Mechanistic / preclinical
MCAS
24 sources
- T6INDIRECT 25420283 ↗ — Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
- T6INDIRECT 26110030 ↗ — Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid:
a systematic review
- T6INDIRECT 26581915 ↗ — A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy
- T6INDIRECT 25200415 ↗ — Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-Ig
- T6INDIRECT 37459086 ↗ — Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penic
- T6INDIRECT 36786791 ↗ — Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2
- T6INDIRECT 24777247 ↗ — T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
- T6INDIRECT 23041624 ↗ — T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection
- T6INDIRECT 24176117 ↗ — A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic pa
- T6 11520916 ↗ — Neurotrophins: roles in neuronal development and function
- T6INDIRECT 17786266 ↗ — Physiology of the autonomic nervous system
- T6INDIRECT 30558872 ↗ — Antibiotic allergy
- T6INDIRECT 18684881 ↗ — Mast cells and mastocytosis
- T6INDIRECT 23939821 ↗ — Key role of CRF in the skin stress response system
- T6INDIRECT 32436290 ↗ — EAACI Allergen Immunotherapy User's Guide
- T6INDIRECT 32128023 ↗ — IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position p
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6 36050306 ↗ — Lactate metabolism in human health and disease
- T6 24587990 ↗ — Oxidative stress, prooxidants, and antioxidants: the interplay
- T6 29467611 ↗ — The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis
- T6 24370461 ↗ — The role of microbiome in central nervous system disorders
- T6 28736339 ↗ — TFOS DEWS II pain and sensation report
- T6 22894052 ↗ — Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine sys
- T6 21134576 ↗ — Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAI
T6 — Mechanistic / preclinical
MCASPOTS
51 sources
- T6INDIRECT 30327483 ↗ — Phenome-wide association studies across large population cohorts support drug target validation
- T6INDIRECT 29861802 ↗ — Low-Level Laser Therapy for Temporomandibular Disorders: A Systematic Review with Meta-Analysis
- T6INDIRECT 35361131 ↗ — Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysi
- T6INDIRECT 32176310 ↗ — A Systematic Review of Drug-Induced Pemphigoid
- T6INDIRECT 31117264 ↗ — Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data
- T6INDIRECT 28709457 ↗ — Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, d
- T6INDIRECT 28779491 ↗ — Antiepileptic drugs for chronic non-cancer pain in children and adolescents
- T6INDIRECT 24085261 ↗ — Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers
- T6INDIRECT 29856741 ↗ — Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with maj
- T6INDIRECT 21834936 ↗ — Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroida
- T6INDIRECT 24554461 ↗ — Echinacea for preventing and treating the common cold
- T6INDIRECT 23076930 ↗ — Local anaesthetics and regional anaesthesia for preventing chronic pain after surgery
- T6INDIRECT 29926477 ↗ — Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent
- T6INDIRECT 24595586 ↗ — Non-surgical interventions for the management of chronic pelvic pain
- T6INDIRECT 22376048 ↗ — American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in o
- T6INDIRECT 31132795 ↗ — Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migr
- T6INDIRECT 31207169 ↗ — The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Do
- T6INDIRECT 15345500 ↗ — A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of A
- T6INDIRECT 28655357 ↗ — Drug-related problems and medication reviews among old people with dementia
- T6INDIRECT 9727818 ↗ — Contrasting actions of pressor agents in severe autonomic failure
- T6INDIRECT 33723532 ↗ — Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrom
- T6INDIRECT 32689643 ↗ — Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights
- T6INDIRECT 29844705 ↗ — Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- T6INDIRECT 27866580 ↗ — Eosinophilia
- T6INDIRECT 24792340 ↗ — Migraine and estrogen
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6INDIRECT 29438602 ↗ — International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- T6INDIRECT 23452057 ↗ — Characterization of different courses of atopic dermatitis in adolescent and adult patients
- T6 25287861 ↗ — Calcitonin gene-related peptide: physiology and pathophysiology
- T6 39174535 ↗ — Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strateg
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 30874629 ↗ — Pain and immunity: implications for host defence
- T6 31275462 ↗ — PEGylated liposomes: immunological responses
- T6 19099185 ↗ — Mcl-1 is a potential therapeutic target in multiple types of cancer
- T6 9092596 ↗ — Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage
- T6INDIRECT 23094876 ↗ — Brugada phenocopy: new terminology and proposed classification
- T6INDIRECT 17915006 ↗ — Hereditary sensory and autonomic neuropathies: types II, III, and IV
- T6INDIRECT 24433463 ↗ — Review of pharmacological therapies in fibromyalgia syndrome
- T6INDIRECT 37139824 ↗ — American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medicatio
- T6INDIRECT 28541649 ↗ — Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulati
- T6INDIRECT 19730409 ↗ — Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-in
- T6 18616962 ↗ — Diabetic neuropathy: mechanisms to management
- T6 23588782 ↗ — Applications of CYP450 testing in the clinical setting
- T6 16461471 ↗ — Diabetic neuropathy
- T6 29315692 ↗ — Comprehensive review of cardiovascular toxicity of drugs and related agents
- T6 30033869 ↗ — A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Ma
- T6 30712918 ↗ — Type 2 diabetes mellitus and osteoarthritis
- T6 10457047 ↗ — Childhood functional gastrointestinal disorders
- T6 26834959 ↗ — Predicting risk of adverse drug reactions in older adults
- T6 31394725 ↗ — Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
- T6 31080465 ↗ — 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Commit
T6 — Mechanistic / preclinical
MCAS
23 sources
- T6INDIRECT 37056675 ↗ — The crucial role and mechanism of insulin resistance in metabolic disease
- T6INDIRECT 37487610 ↗ — The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected h
- T6INDIRECT 15741434 ↗ — Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmona
- T6INDIRECT 33085861 ↗ — Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
- T6INDIRECT 32719045 ↗ — Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive
- T6INDIRECT 37459086 ↗ — Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penic
- T6INDIRECT 20067641 ↗ — Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis accordin
- T6INDIRECT 25154820 ↗ — Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effect
- T6 34054126 ↗ — Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
- T6 30324412 ↗ — European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- T6INDIRECT 32196678 ↗ — Eleven faces of coronavirus disease 2019
- T6INDIRECT 17655751 ↗ — Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis
- T6INDIRECT 33649022 ↗ — Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management
- T6INDIRECT 32803422 ↗ — Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a com
- T6INDIRECT 24366648 ↗ — Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations
- T6INDIRECT 32436290 ↗ — EAACI Allergen Immunotherapy User's Guide
- T6INDIRECT 23109216 ↗ — Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for p
- T6INDIRECT 26525001 ↗ — 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
- T6 26228647 ↗ — Colchicine--Update on mechanisms of action and therapeutic uses
- T6 18266020 ↗ — European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- T6 32376392 ↗ — Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventio
- T6 32467561 ↗ — Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered
- T6 23079689 ↗ — European guidance for the diagnosis and management of osteoporosis in postmenopausal women
No agents match this search.